[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 2753
1. Hashmi KU, Khan B, Ahmed P, Raza S, Hussain I, Mahmood A, Iqbal H, Malik HS, Anwar M: FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. J Pak Med Assoc; 2005 Jun;55(6):234-8
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
  • OBJECTIVE: To evaluate the efficacy and toxicity profile of the combination of fludarabine, high dose cytarabine, idarubicin, and granulocyte colony stimulating factor in refractory relapsed cases of acute leukaemia, a study is being conducted at Armed Forces Bone Marrow Transplant Centre (AFBMTC) Rawalpindi since January 2003.
  • METHODS: Twelve Patients with refractory/relapsed (Ref/Rel) acute leukaemia (AL) were treated with fludarabine 30 mg/m2 and cytosine arabinoside (AraC) Arac 2 g/m2 for 5 days, idarubicin 10 mg/m2 for 3 days, and granulocyte colony stimulating factor G-CSF 5 micro g/kg from day 0 till neutrophil recovery (ANC > 1.0 x 10(9)/1).
  • RESULTS: Patients included were refractory acute lymphoblastic leukaemia (ALL) (n=2), relapsed ALL (n = 3), refractory acute myeloid leukaemia (AML) (n = 3), secondary AML (n=2) relapsed AML (n = 1) and acute undifferentiated leukaemia (AUL) (n = 1).
  • CONCLUSION: In our experience, FLAG-IDA is well tolerated and effective regimen in relapsed/refractory acute leukaemias.
  • The toxicity is acceptable, enabling most patients to receive further treatment, including transplantation procedures.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / therapeutic use. Child. Cytarabine / therapeutic use. Female. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Idarubicin / therapeutic use. Male. Middle Aged. Recurrence

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045091.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


2. Saxena R, Anand H: Flow cytometry in acute leukemia. Indian J Hematol Blood Transfus; 2008 Dec;24(4):146-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometry in acute leukemia.
  • Immunophenotyping of acute leukemia is one of the most important clinical application of Flow cytometery.
  • The aim of this work is to review recent advances in flow cytometery methods, quality control, troubleshooting and its prevention and data analysis of acute leukemia.
  • Multiparameter flow cytometery is a useful adjunct to morphology and cytochemistry and it is an invaluable tool in the diagnosis of acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1251-65 [11147222.001]
  • [Cites] Semin Hematol. 2001 Apr;38(2):124-38 [11309694.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:313-21 [12095957.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2264-70 [17611554.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3941-67 [18198345.001]
  • (PMID = 23100953.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3475429
  • [Keywords] NOTNLM ; Acute leukemia / Flow cytometery / Immunophenotyping / Leukemia
  •  go-up   go-down


3. Serra-Bonett N, Guzmán Y, Rodríguez E, Millán A, Rodríguez MA: [Acute leukemia in children erroneously diagnosed as idiopathic juvenile arthritis]. Reumatol Clin; 2008 Mar;4(2):70-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute leukemia in children erroneously diagnosed as idiopathic juvenile arthritis].
  • [Transliterated title] Leucemia aguda en niños con diagnóstico erróneo de artritis idiopática juvenil.
  • We here present 3 Venezuelan children with acute leukemia, initially diagnosed as idiopathic juvenile arthritis because of the occurrence of pain and joint swelling at the onset of disease.
  • One patient presented with persistent unilateral sacroiliac pain leading to a wrong diagnosis of spondyloarthritis.
  • The elevation of acute phase reactants, disproportionate to the extent of joint disease, and marked elevation of serum lactate dehydrogenase, as well as characteristicradiological changes allowed the correct diagnosis in all cases.
  • This combination of clinical manifestations, clinical laboratory findings, and joint and bone imaging should prompt the clinician to an early diagnosis of acute leukemia in children with arthritis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 Elsevier España. Reumatología Clínica ® Sociedad Española de Reumatología and ® Colegio Mexicano de Reumatología. Published by Elsevier Espana. All rights reserved.
  • (PMID = 21794501.001).
  • [ISSN] 1699-258X
  • [Journal-full-title] Reumatología clinica
  • [ISO-abbreviation] Reumatol Clin
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Belacel N, Wang Q, Richard R: Web-integration PROAFTN methodology for acute leukemia diagnosis. Telemed J E Health; 2005 Dec;11(6):652-9
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Web-integration PROAFTN methodology for acute leukemia diagnosis.
  • OBJECTIVE: To develop and test a web-based Clinical Decision Support System (CDSS) tool, which integrated a new fuzzy multiple criteria classification methodology named PROAFTN in acute leukemia (AL) diagnosis.
  • 1) make a "virtual" diagnosis and to compare its performances with given clinical diagnosis;.
  • The method will not replace specialists, but was developed to assist biologist-hematologists and general practitioners remotely in making decisions on medical diagnosis.
  • [MeSH-major] Decision Support Systems, Clinical / organization & administration. Internet. Leukemia / diagnosis. Systems Integration
  • [MeSH-minor] Acute Disease. Humans. New Brunswick. Software

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16430384.001).
  • [ISSN] 1530-5627
  • [Journal-full-title] Telemedicine journal and e-health : the official journal of the American Telemedicine Association
  • [ISO-abbreviation] Telemed J E Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Puumala SE, Ross JA, Olshan AF, Robison LL, Smith FO, Spector LG: Reproductive history, infertility treatment, and the risk of acute leukemia in children with down syndrome: a report from the Children's Oncology Group. Cancer; 2007 Nov 1;110(9):2067-74
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reproductive history, infertility treatment, and the risk of acute leukemia in children with down syndrome: a report from the Children's Oncology Group.
  • BACKGROUND: Children with Down syndrome (DS) have from 10 to 20 times the risk of developing acute leukemia than the general pediatric population.
  • There is mixed evidence for associations between reproductive history or infertility and acute leukemia among children without DS.
  • METHODS: The authors conducted a case-control study of acute leukemia among children with DS to investigate possible risk factors in this population.
  • From 1997 to 2002, 158 children aged <20 years with DS who had a diagnosis of acute leukemia (97 children with acute lymphoblastic leukemia [ALL] and 61 children with acute myeloid leukemia [AML]) were enrolled at Children's Oncology Group (COG) institutions.
  • RESULTS: Null results were observed overall and by subtype for reproductive factors, including previous pregnancy outcomes and contraceptive use, and for most infertility outcomes.
  • [MeSH-major] Down Syndrome / complications. Infertility / therapy. Leukemia / complications. Reproductive History
  • [MeSH-minor] Acute Disease. Case-Control Studies. Child. Child, Preschool. Female. Fertility Agents, Female / adverse effects. Fertilization in Vitro / adverse effects. Humans. Male. Maternal Age. Mothers. Pregnancy. Prenatal Exposure Delayed Effects. Risk Factors. Sperm Injections, Intracytoplasmic / adverse effects


6. Gluzman DF, Nadgornaya VA, Sklyarenko LM, Ivanovskaya TS, Poludnenko LY, Ukrainskaya NI: Immunocytochemical markers in acute leukaemias diagnosis. Exp Oncol; 2010 Sep;32(3):195-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytochemical markers in acute leukaemias diagnosis.
  • The study included 1742 patients with acute myeloblastic leukaemias (AML) and acute lymphoblastic leukaemias (ALL), Kyiv city residents and patients from 20 regions of Ukraine.
  • Bone marrow and blood smears were sent at diagnosis to Reference Center.
  • Immunocytochemical techniques (APAAP, LSAB) and broad panel of monoclonal antibodies (MoAbs) against lineage specific and differentiation antigens of leukocytes were employed for immunophenotyping of leukemic blast cells directly in blood and bone marrow smears.
  • Different types of AML were defined by the expression of the cell surface and cytoplasmic antigens.
  • Immunocytochemical study was required especially in diagnosing of AML with minimal differentiation, acute megakaryoblastic leukaemia, acute erythroid leukaemia and acute leukaemias of ambiguous lineage.
  • Acute lymphoblastic leukaemias was broadly classified into B-lineage and T-lineage ALL.
  • According to the degree of B-lymphoid differentiation of the blast cells four subtypes of B-lineage ALL were established.
  • Immunocytochemical examination was required to diagnose AL of ambiguous lineage with no clear evidence of lineage differentiation (acute undifferentiated leukaemia) or those with blasts that express markers of more than one lineage (mixed phenotype acute leukaemias).
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / immunology. Humans. Immunohistochemistry. Immunophenotyping. Lymphocyte Subsets / immunology. Lymphocyte Subsets / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21403617.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


7. Lim CK, Goh YT, Hwang WY, Ho LP, Sun L: Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore. Biomark Insights; 2007 Aug 08;2:293-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Studies of Wilms' Tumor (WT1) Gene Expression in Adult Acute Leukemias in Singapore.
  • Biomarkers provide certain values for diagnosis, monitor treatment efficacy, or for the development of novel therapeutic approach for particular diseases.
  • Thus, the identification of specific of biomarkers for specific medical problems, including malignant diseases may be valuable in medical practice.
  • In the study, we have used the Wilms' tumor gene (WT1) as a biomarker to evaluate its expression in local adult patients with newly diagnosed acute leukemia, including both acute myeloid and lymphoid leukemias (AML and ALL).
  • AIM: To investigate WT1 gene expression in adult patients with acute leukemia at diagnosis.
  • METHODS: Eighteen patients with acute leukemia diagnosed at Singapore General Hospital, Singapore, between September, 2004 and July, 2005 were included in this study.
  • RESULTS: WT1 gene was exclusively expressed in all eighteen, including three ALL and fifteen AML, patients.
  • CONCLUSIONS: WT1 gene expression was observed in local patients with acute leukemia at diagnosis.
  • It may be used as a potential molecular marker for diagnosis, clinical progression of the diseases or monitoring the response to treatment, as well as a target for the development of novel therapeutic approaches.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 1990 Feb 22;343(6260):774-8 [2154702.001]
  • [Cites] Cell. 1990 Feb 9;60(3):509-20 [2154335.001]
  • [Cites] Blood. 2003 Jul 15;102(2):773-4; author reply 774 [12835231.001]
  • [Cites] Blood. 2002 Nov 15;100(10):3835-7 [12411326.001]
  • [Cites] Int J Hematol. 2002 Aug;76(2):103-9 [12215007.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Aug;11(4):589-99 [12201948.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1167-71 [12006533.001]
  • [Cites] EMBO J. 2001 Jan 15;20(1-2):197-209 [11226170.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):921-5 [11221883.001]
  • [Cites] Blood. 2000 Apr 1;95(7):2198-203 [10733485.001]
  • [Cites] Blood. 2000 Jan 1;95(1):286-93 [10607714.001]
  • [Cites] J Biol Chem. 2006 Sep 22;281(38):28122-30 [16698800.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1293-8 [16533527.001]
  • [Cites] Nucl Recept Signal. 2003;1:e012 [16604184.001]
  • [Cites] Methods Mol Med. 2006;125:199-211 [16502587.001]
  • [Cites] Arch Pharm Res. 2006 Jan;29(1):80-7 [16491848.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Dec;24(4):595-9 [16471322.001]
  • [Cites] Leukemia. 2006 Feb;20(2):254-63 [16341043.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1405-12 [9028964.001]
  • [Cites] Genome Res. 1996 Oct;6(10):986-94 [8908518.001]
  • [Cites] Oncogene. 1996 Mar 7;12(5):1005-14 [8649791.001]
  • [Cites] Blood. 1994 Nov 1;84(9):3071-9 [7949179.001]
  • [Cites] Leukemia. 1992 May;6(5):405-9 [1317488.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • (PMID = 19662212.001).
  • [Journal-full-title] Biomarker insights
  • [ISO-abbreviation] Biomark Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2717842
  • [Keywords] NOTNLM ; HLA-A / WT1 / adulthood acute leukemia / gene expression
  •  go-up   go-down


8. Li X, Du W, Liu W, Li X, Li H, Huang SA: Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS; 2010 May;118(5):353-9
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
  • Multiparameter flow cytometry (MFC) plays a vital role in the detection of minimal residual disease (MRD) and diagnosis of relapse in acute leukemia.
  • However, application of a limited panel of antibodies in MFC leads to high rates of false-negative and false-positive results.
  • Thirteen patients with acute lymphoblastic leukemia (ALL) and 12 patients with acute myeloid leukemia (AML) were immunophenotyped by MFC at diagnosis and at relapse using a comprehensive panel of monoclonal antibodies (McAbs) to 27 antigens and CD45/SSC gating.
  • In 23 of 25 patients (92.3%), changes in at least one of progenitor-associated, myeloid and lymphoid antigens between diagnosis and relapse were observed.
  • Multiple panels of three or more McAbs are likely to be required in the monitoring of MRD and diagnosis of relapse in acute leukemia by MFC.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477810.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


9. Zhao Y, Yu L, Wang QS, Li HH, Bo J, Wang SH, Jin HJ, Lou FD: [Id4 gene methylation for detection of minimal residual disease in acute leukemia]. Zhonghua Xue Ye Xue Za Zhi; 2006 May;27(5):298-301
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Id4 gene methylation for detection of minimal residual disease in acute leukemia].
  • OBJECTIVE: To evaluate the possibility of Id4 gene promoter methylation as a biomarker for minimal residual disease (MRD) detection in acute leukemia.
  • METHODS: Methylation specific-PCR technique was used to detect Id4 gene methylation in samples with different percentages of leukemia cells from leukemia cell line and bone marrows from leukemia patients in complete remission (CR).
  • RESULTS: Id4 gene methylation could be detected in samples containing 1% or lower leukemia cells.
  • Frequency of Id4 gene methylation in acute lymphoblastic leukemia (ALL) patients in CR was 64.3% being higher than that in acute myeloid leukemia (AML) patients in CR.
  • CONCLUSION: Id4 gene promoter methylation is a candidate of biomarker for MRD detection in acute leukemias.
  • [MeSH-major] DNA Methylation. Inhibitor of Differentiation Proteins / genetics. Leukemia / diagnosis. Neoplasm, Residual / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Cell Line. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875575.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins
  •  go-up   go-down


10. Ali R, Ozkalemkas F, Ozkocaman V, Ozcelik T, Akalin H, Ozkan A, Altundal Y, Tunali A: Hydatid disease in acute leukemia: effect of anticancer treatment on echinococcosis. Microbes Infect; 2005 Jul;7(9-10):1073-6
Hazardous Substances Data Bank. AMPHOTERICIN B .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydatid disease in acute leukemia: effect of anticancer treatment on echinococcosis.
  • Echinococcosis, also known as hydatid disease or hydatidosis, is a zoonotic illness caused by the larval form of Echinococcus spp.
  • We treated and followed approximately 1200 patients with different hematologic neoplastic diseases between 1985 and 2003, and only one of these individuals had concomitant acute leukemia and liver hydatidosis.
  • This report describes the case of a 19-year-old man who had both primary refractoriness of acute leukemia (AML-M4) and liver hydatidosis.
  • The patient underwent 3 months of treatment with agents that targeted the leukemia (daunorubicin, idarubicin, cytarabine, fludarabine) and its complications (amphotericin B, amphotericin B lipid complex, liposomal amphotericin B).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996888.001).
  • [ISSN] 1286-4579
  • [Journal-full-title] Microbes and infection
  • [ISO-abbreviation] Microbes Infect.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


11. Liang T, Wang N, Li W, Li A, Wang J, Cui J, Liu N, Li Y, Li L, Yang G, Du Z, Li D, He K, Wang G: Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment. Proteomics; 2010 Jan;10(1):90-8
Hazardous Substances Data Bank. (L)-ARGININE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of complement C3f-desArg and its derivative for acute leukemia diagnosis and minimal residual disease assessment.
  • Therapeutic conditions for acute leukemia (AL) mainly rely on diagnosis and detection of minimal residual disease (MRD).
  • However, no serum biomarker has been available for clinicians to make diagnosis of AL and assessment of MRD.
  • [MeSH-major] Biomarkers, Tumor / blood. Complement C3b / analysis. Leukemia / blood. Neoplasm, Residual / blood
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Amino Acid Sequence. Arginine / metabolism. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Proteomics. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19882663.001).
  • [ISSN] 1615-9861
  • [Journal-full-title] Proteomics
  • [ISO-abbreviation] Proteomics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / complement C3f-des-arginine; 80295-43-8 / Complement C3b; 94ZLA3W45F / Arginine
  •  go-up   go-down


12. Sun XL, Fang MY, Jiang F, Jing Y: [Immunologic classification used in typing of 68 cases of acute leukemias]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Feb;14(1):39-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Immunologic classification used in typing of 68 cases of acute leukemias].
  • To evaluate the significance of immunologic classification for typing of acute leukemia (AL).
  • 68 cases of AL were classified by morphologic and immunologic typings.
  • The results showed that the consistency rate was 94.1% between morphology and immunology, and 4 morphologic misdiagnosed cases were corrected by immunology; CD13 and CD33 were special myeloid lineage-associated antigens; AML-M(3) was often CD34 low-expressed and HLA-DR-negative; CD14 was often expressed in AML-M(4) and M(5); lymphoid lineage-associated antigens (CD7) were easily found in ANLL, and myeloid lineage-associated antigens were also found in ALL.
  • In conclusion, immunologic classification can improve the accuracy in acute leukemia diagnosis.
  • The diagnosis of some special AL, such as acute unidentified leukemia (AUL), AML-M(0) and so on, must rely on immunologic classification.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16584588.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, CD34; 0 / Antigens, CD7; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD33 protein, human; 0 / Sialic Acid Binding Ig-like Lectin 3; EC 3.4.11.2 / Antigens, CD13
  •  go-up   go-down


13. Kirschnerová G, Tóthová A, Babusíková O: Amplification of AML1 gene in association with karyotype, age and diagnosis in acute leukemia patients. Neoplasma; 2006;53(2):150-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of AML1 gene in association with karyotype, age and diagnosis in acute leukemia patients.
  • AML1 is normally expressed in all hematopoietic lineages and is essential for the transcriptional regulation of a number of hematopoietic specific genes.
  • In acute leukemia three types of abnormality of AML1 have been observed -- chromosomal translocations, point mutation and duplication or amplification of the unrearranged gene.
  • [MeSH-major] Core Binding Factor Alpha 2 Subunit / genetics. Gene Amplification. Leukemia / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Child. Child, Preschool. Chromosome Aberrations. Female. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575471.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / RUNX1 protein, human
  •  go-up   go-down


14. Wu YJ, Li JY, Zhu MQ, Song JH, Zheng WJ: [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens]. Zhonghua Xue Ye Xue Za Zhi; 2006 Jul;27(7):449-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Application of a four antibody (cMPO/cCD79aalpha/cCD3/CD45) combination to the diagnosis of acute leukemia expressing cross-lineage antigens].
  • OBJECTIVE: To explore the diagnostic value of intracellular antibody combination in acute leukemia (AL) expressing cross-lineage cell-surface antigens.
  • RESULTS: Fifty-four of 269 previously untreated adult AL patients who expressed only one kind of intracellular antigen were diagnosed as cross-lineage AL, the percentage of cross-lineage AL in T cell acute lymphoblastic leukemia (T-ALL), B-ALL and acute myeloid leukemia (AML) was 28.6%, 43.6% and 13.4%, respectively.
  • Six (2.3%) patients expressed two-lineage intracellular antigens were diagnosed as biphenotypic AL: 2 of T/B type and 4 B/M (B/myeloid) type.
  • [MeSH-major] Antibodies, Monoclonal. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147246.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD3; 0 / Antigens, CD79; 0 / Antigens, Surface; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


15. Rao SR, Hassett M, Schwartz JH, Maloney B, Jacobson JO: Admissions for chemotherapy-related serious adverse effects (CR-SAEs) and rates of mortality among community cancer center patients. J Clin Oncol; 2009 May 20;27(15_suppl):6571

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We conducted a prospective cohort study of adult cancer patients (excluding acute leukemia and stem cell transplant patients) admitted to a community hospital January 2003-December 2006.
  • We identified the type of SAE, outcome of each admission, time form chemotherapy to admission and from admission to discharge/death, and the disease and treatment characteristics of each patient.
  • The average time from chemotherapy to admission was shorter for fatal vs. non-fatal admissions (3.6 vs. 7.7 days; p<.01).
  • CONCLUSIONS: Fatalities during admissions for CR-SAE's in a community cancer center are relatively uncommon and are not associated with age or type of SAE/cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963798.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Pigazzi M, Manara E, Baron E, Beghin A, Basso G: The inducible cyclic adenosine 3',5'-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):e22045

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The inducible cyclic adenosine 3',5'-monophosphate early repressor (ICER) enhances drug sensitivity in acute myeloid leukemia.
  • CREB was previously demonstrated to be overexpressed in acute leukemia, whereas ICER was found rapidly degradated being unable to control gene transcription.
  • ICER exogenous expression was demonstrated to repress CREB targets preventing leukemia progression.
  • We hypothesized that ICER restoration deserves a special consideration for playing a role in CREB oncogenic feature and in modeling leukemic cell phenotype.
  • We monitored transcription and translation of a series of genes involved in different pathways by quantitative gene expression and western blot analysis.
  • We investigate ICER's role in cell death after treatment with chemotherapic drugs.
  • RESULTS: We revealed that ICER was able to control gene expression in leukemia, principally of genes involved in cell death and survival.
  • Cell cycle analyses revealed a block in G2 phase, a lowered cell proliferation and clonogenic potential with respect to HL60 treated at the same conditions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963227.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Pratz KW, Cho E, Karp J, Levis M, Zhao M, Rudek M, Wright J, Smith BD: Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias. J Clin Oncol; 2009 May 20;27(15_suppl):7065

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I dose escalation trial of sorafenib as a single agent for adults with relapsed and refractory acute leukemias.
  • Based on preclinical activity in FLT3 mutant AML, sorafenib was studied in refractory acute leukemia.
  • METHODS: The primary objective was to determine the safety and tolerability of sorafenib in refractory acute leukemias.
  • No patients met criteria for complete or partial response, but 11 of 15 (73%) patients experienced stable disease as best response, with 6 showing a reduction in bone marrow blasts after only one cycle, half of who experienced a >50% reduction in bone marrow blasts.
  • Interestingly, 2 pts with FLT3-ITD mutations both showed marrow blast response (1 pt >50%).
  • Clinical activity as a single agent was limited to transient reductions in bone marrow blast counts and dose escalation was limited due to toxicities.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961441.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Duhoux F, Libouton J, Bahloula K, Ameye G, Poirel HA: Identification by FISH of 4 novel partner loci of PRDM16 in myeloid malignancies. J Clin Oncol; 2009 May 20;27(15_suppl):11037

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 11037 Background: PRDM16 is a gene located on 1p36.32 that encodes for a zinc finger transcription factor and contains an N-terminal PR domain.
  • It has been shown to be involved in the reciprocal translocation t(1;3)(p36;q21) and more rarely the t(1;21)(p36;q22) which both occur in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML).
  • These translocations result in the overexpression of a truncated version of the PRDM16 protein that lacks the PR domain.
  • METHODS: We studied 35 myeloid malignancies, 12 lymphoid malignancies and 3 undifferentiated acute leukemias with 1p36 abnormalities by fluorescent in situ hybridization (FISH) with a bacterial artificial chromosomes (BAC) contig containing 50 BAC probes on 1p36.
  • We identified the respective candidate partner loci : TEL/ETV6, IKZF1, CDH4 and a non-coding unknown sequence.
  • Interestingly, the shortest isoform of MDS/EVI-1, lacking the PR domain, is supposed to have an oncogenic effect due to its translocation-induced upregulation in AML.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964015.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Faderl S, Thomas DA, Gandhi V, Huang X, Borthakur G, O'Brien S, Ravandi F, Plunkett W, Bretz JL, Kantarjian HM: Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL). J Clin Oncol; 2009 May 20;27(15_suppl):7020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL).
  • Twenty-one pts had pre-B ALL, 5 pts pre-T/T ALL, 1 pt mature B ALL, and 3 pts biphenotypic acute leukemias.
  • One (20%) pt in cohort 1 and 9 (36%) in cohort 2 experienced DLTs (≥ grade 3) including transaminase elevations, diarrhea, hyperbilirubinemia, and (1 pt each) elevation of creatinine/renal failure, lipase elevation, rash, nausea/vomiting.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961382.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Mohty M, Balere M, Socie G, Milpied N, Ifrah N, Harousseau JL, Michallet M, Blaise D, Esperou H, Yakoub-Agha I, SFGM-TC: Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD). J Clin Oncol; 2009 May 20;27(15_suppl):7025

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of antithymocyte globulins (ATG) as part of the myeloablative conditioning (MAC) regimen on the risk of severe graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) from matched-unrelated donors (MUD).
  • : 7025 Here, we report the results of a multicenter retrospective study analyzing the effect of ATG, incorporated within the MAC regimen for MUD-transplants in leukemic patients.
  • The purpose of the study was to compare the incidence and severity of acute and chronic GVHD as well as overall outcome.
  • 171 adult patients with acute leukemia and MDS, for whom detailed allelic HLA typing (4 digits) was available, were included.
  • With a median follow-up of 30.3 (range, 2.6-68.1) months, grade 0-1 and 2-4 acute GVHD occurred in 74 (46%) and 88 patients (54%) respectively, with grade 3-4 acute GVHD being significantly lower in the ATG group (18% vs. 32%; p = 0.04).
  • In multivariate analysis, an HLA allelic mismatch and the non-use of ATG were associated with an increased risk of grade 3-4 acute GVHD (RR = 2.80, 95% CI, 1.5-5.3, p = 0.001; and RR = 2.4, 95% CI, 1.1-5.0, p = 0.02 respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961398.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Bloomfield CD: Importance of genetic heterogeneity in curing adult acute leukemia (AL). J Clin Oncol; 2009 May 20;27(15_suppl):s1

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Importance of genetic heterogeneity in curing adult acute leukemia (AL).
  • Publication of the French-American-British classification 34 years ago resulted in acceptance that morphology and cytochemistry separated AL into two different diseases, acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), that required separate treatment.
  • The most striking example of increased curability of AL is acute promyelocytic leukemia, in which targeted therapy combined with chemotherapy has increased survival from a 2-week median to an 80% cure rate.
  • Recognition of increased sensitivity of a genetic subtype of AML to high-dose cytarabine (HiDAC) has increased the cure rate of core-binding factor (CBF) AML from <10%-25% to 55%-60%.
  • Among adult de novo AML 40%-45% are cytogenetically normal (CN); the striking molecular heterogeneity of CN-AML is now being recognized and promises to allow individualized approaches that improve substantially upon the current cure rate of 40%.
  • New approaches to studying the leukemia genome and epigenome should improve our understanding of AL heterogeneity, identify new therapeutic targets, and allow the cure of most patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962366.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Lopez-Enriquez AT: Acute promielocytic leukemia: 14 years experience at the University Hospital, San Juan, Puerto Rico. J Clin Oncol; 2009 May 20;27(15_suppl):e18006

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute promielocytic leukemia: 14 years experience at the University Hospital, San Juan, Puerto Rico.
  • : e18006 Background: Acute promielocytic leukemias (APL) are a unique example in carcinogenesis, of maturation arrest at the promielocytic stage, associated with a chromosomal reciprocal translocation of a portion of chromosome 15 and 17 with the formation of fusion proteins between the PML gene and the alpha-retinoic acid receptor site.
  • METHODS: Since 1994 when transretinoic acid (ATRA) became available to us, we developed a protocol incorporating this drug to the standard regime of induction chemotherapy for acute leukemias used in our institution of 7 days of continuous infusion of cytosine arabinoside (Ara-C) and three days of daunorubicine (7+3), starting the ATRA on day 14 at 45 mg/m2 and continued daily for 120 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963993.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Tagawa ST, Parmar S, Pena J, Petrillo K, Matulich D, Selzer J, Vallabhajosula S, Goldsmith SJ, Bander NH, Nanus DM: Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC). J Clin Oncol; 2009 May 20;27(15_suppl):e16004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cases of marrow damage, including myelodysplasia and acute leukemia have been reported with the RIT most used to date (that targeting CD20 in Non- Hodgkin's lymphoma), though no statistically significant association exists.
  • Specific searches for subsequent myelodysplasia and/or leukemia were performed.
  • No cases of post-RIT myelodysplasia and/or leukemia were discovered.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962929.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Ghavamzadeh A, Allahyari A, Alimoghaddam K, Karimi A, Shamshiri A, Abolhasani R, Manookian A, Asadi M, Khatami F: Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders. J Clin Oncol; 2009 May 20;27(15_suppl):7042

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outpatient versus inpatient autologous stem cell transplantation for malignant hematologic disorders.
  • : 7042 Background: High-dose chemotherapy with autologous stem cell support is utilized for the treatment of a variety of malignancies including Hodgkin/non-Hodgkins lymphoma and acute leukemias.
  • The aim of this study was to compare the time of engraftment and mortality rate and cost of neutropenic treatment in outpatient versus inpatient autologous stem cell transplantation (SCT).
  • They received conditioning regimen (CEAM for NHL and HL, busulfan and etoposide for AML) and stem cell infusion in hospital.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961405.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kadia TM, Faderl S, Estrov Z, Konopleva M, George S, Lee W, Puzanov I, Chen A, Kantarjian H, Ravandi F: Final results of phase I and pharmacokinetic study of SJG-136 administered on a daily x 5 schedule. J Clin Oncol; 2009 May 20;27(15_suppl):e13506

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we report the results of a CTEP-sponsored phase I trial of SJG-136 administered on a daily x 5 schedule in pts with relapsed or refractory (R/R) leukemias.
  • METHODS: Previously treated pts with R/R acute leukemias (AML, ALL, high risk MDS, CML blast phase) or R/R CLL with adequate organ function and ECOG performance status of ≤ 2 were eligible for the study.
  • Other manifestations of vascular leak including grade I, II hypoalbuminemia, edema, and pleural effusions were seen in a number of patients starting at dose level 24 mcg/m<sup>2</sup> and above.
  • Other non-dose limiting toxicities included nausea, dyspnea, fatigue, bloating, and insomnia.
  • One pt had a PR, 8 pts had stable disease, and 6 had progression.
  • CONCLUSIONS: SJG-136 is safe and active in patients with advanced leukemias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961262.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Nikolic NM, Tomasevic Z, Jelic S: Secondary malignancies developing during metastatic breast cancer treatment. J Clin Oncol; 2009 May 20;27(15_suppl):e12020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e12020 Background: Secondary malignancies (SM) developing during metastatic breast cancer (MBC) are obviously more complicated for diagnosis, potential surgery and for further MBC treatment.
  • Patients with contra-lateral BC and acute leukemia were excluded.
  • CONCLUSIONS: According to our experience, SM develops more frequently in MBC than in non MBC patients, representing 60% (30/50 patients) of all SM in BC patients; 46.6% (14/30) of SM diagnosed during MBC could be surgically resected, and does not influence further MBC treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964310.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rangarajan B, Prabhash K, Nair R, Menon H, Jain P, Kannan S, Jeevangi NK, Bagal B, Parikh PM, Kurkure PA: Rater. J Clin Oncol; 2009 May 20;27(15_suppl):e20678

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria were diagnosis of hematolymphoid malignancy, neutropenic febrile episode secondary to chemotherapy or during induction therapy of acute leukemia and more than 18 years of age All patients were risk stratified, hospitalized and treated with broad-spectrum, empiric, intravenous antibiotic therapy until recovery or outcome of the event.
  • We subsequently analyzed the subset of Acute Myeloid Leukemia (AML) patients as they were the majority comprising of 62/81 episodes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961676.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Mayer F, Weidmann J, Federmann B, Schwarz S, Hartmann JT, Kanz L, Bethge W: Clinical impact and follow-up of taste disturbances following myeloablative or nonmyeloablative chemotherapy and stem cell transplantation. J Clin Oncol; 2009 May 20;27(15_suppl):e20609

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact and follow-up of taste disturbances following myeloablative or nonmyeloablative chemotherapy and stem cell transplantation.
  • : e20609 Background: Stem cell transplantation (SCT) after myeloablative (MA) or non-myeloablative (NMA) chemotherapy is a successful treatment option for a variety of diseases.
  • Indications for SCT included acute leukemia (n=38), myeloproliferative disease (n=20), lymphoma (n=13), and others (n=29).
  • 75% of pts reported moderate to severe changes in taste perception on a semiquantitative visual analogue scale during the acute phase of SCT with no differences between the three groups (73%, 79%, 75%).
  • The lower incidence of persiting changes in taste perception after autologous SCT might be attributed to the absence of graft versus host disease or the dispensability of immunosuppression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961552.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Plunkett W, Thomas DA, O'Brien SM, Federl S, Giles FJ, Nicol SJ, Gill J, Zhao L, Ravandi F, Kantarjian H: Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia. J Clin Oncol; 2009 May 20;27(15_suppl):7068

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I study of pemetrexed in patients with relapsed or refractory acute leukemia or lymphoid blast phase chronic myelogenous leukemia.
  • The purpose of this phase I trial was to define the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of pemetrexed given with vitamin supplementation to patients with relapsed or refractory leukemia.
  • METHODS: Patients ≥15 years of age were enrolled with relapsed or refractory leukemia, Eastern Cooperative Oncology Group performance status ≤2, adequate renal and hepatic function, and life expectancy of ≥6 weeks.
  • RESULTS: Twenty-two patients entered the trial; median age was 50 years (range: 18-75); 15 patients had acute myeloid leukemia and 7 patients had acute lymphocytic leukemia (ALL).
  • Two patients died during the study due to disease progression and 1 patient discontinued due to a subdural hematoma of unknown cause.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961463.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Spanaki A, Linardakis E, Perdikogianni C, Stiakaki E, Morotti A, Cilloni D, Kalmanti M: Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia. Leuk Res; 2007 Apr;31(4):570-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia.
  • The purpose of this study was to investigate WT1 expression levels in childhood acute leukemia.
  • Bone marrow from 14 children with acute leukemia at diagnosis and from 7 children with solid tumors without bone marrow involvement (control group) was studied.
  • Four of the five WT1 positive patients with additional adverse prognostic factors, have succumbed to their disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. WT1 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16876863.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


31. Savchenko VG: [Acute leukemia and pregnancy--some postulates]. Ter Arkh; 2009;81(7):5-7
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute leukemia and pregnancy--some postulates].
  • The aim of chemotherapy of acute leukemia in pregnant women is to save two lives.
  • Abortion is not mandatory in acute leukemia as this disease is curable by chemotherapy.
  • Effective treatment of pregnant women with acute leukemia diagnosis is now practiced not only by large clinics, it is also provided by regional centers.
  • Overall 5-year actual survival for acute myeloid leukemia is 64%, for APL and ALL - 25%.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Acute Disease. Disease-Free Survival. Embryonic Development / drug effects. Female. Fetal Development / drug effects. Humans. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708566.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


32. Zhao Y, Li HH, Bo J, Jing Y, Wang SH, Wang QS, Dou LP, Sun JF, Yu L: [Investigation on MS-PCR as a method for detecting minimal residual disease in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):455-8
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation on MS-PCR as a method for detecting minimal residual disease in acute leukemia].
  • The aim of this study was to investigate the feasibility of monitoring minimal residual disease (MRD) of leukemia with methylation specified-polymerase chain reaction (MS-PCR).
  • The MS-PCR technique was used to detect the methylation status of Id4 gene in different ratios of leukemia cells.
  • In conclusion, the MS-PCR technique can detect the Id4 gene methylation in leukemia cell sample containing 0.1% of HL-60 cells, moreover the Id4 gene methylation in various leukemia cells shows no significant difference, thereby use of MS-PCR to detect the Id4 methylation level may be a potential approach for monitoring of MRD.
  • Id4 gene promoter methylation is a candidate of biomarker for MRD detection in acute leukemias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379587.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ID4 protein, human; 0 / Inhibitor of Differentiation Proteins
  •  go-up   go-down


33. Nowakowska-Kopera A, Sacha T, Florek I, Zawada M, Czekalska S, Skotnicki AB: Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia. Leuk Lymphoma; 2009 Aug;50(8):1326-32
Genetic Alliance. consumer health - Wilms' tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 expression analysis by real-time quantitative polymerase chain reaction for monitoring of minimal residual disease in acute leukemia.
  • Wilms' tumor gene 1 (WT1) gene expression was analyzed in 32 patient with acute myeloid leukemia (AML) and 18 with acute lymphoblastic leukemia (ALL) to investigate whether it could serve as a MRD marker.
  • Ninety-four percent of patients with acute leukemia showed high WT1 expression at presentation.
  • WT1 expression analysis could be a useful tool for MRD monitoring in acute leukemia.
  • [MeSH-major] Gene Expression Regulation, Leukemic. Genes, Wilms Tumor. Leukemia, Myeloid / genetics. Neoplasm Proteins / biosynthesis. Polymerase Chain Reaction / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. WT1 Proteins / biosynthesis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Computer Systems. Disease-Free Survival. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm, Residual / chemistry. Neoplasm, Residual / diagnosis. Prognosis. Proportional Hazards Models. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19811333.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / WT1 Proteins
  •  go-up   go-down


34. Oztürkmen S, Akyay A, Biçakçi Z, Karakoç Y, Arikan SM, Celebi-Tayfur A, Ağladioğlu S, Olcay L: Delayed diagnosis of acute leukemia in a patient with bone pain and fracture. Turk J Pediatr; 2010 Sep-Oct;52(5):552-5
MedlinePlus Health Information. consumer health - Arm Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Delayed diagnosis of acute leukemia in a patient with bone pain and fracture.
  • In childhood acute lymphoblastic leukemia (ALL), non-hematological manifestations involving the musculoskeletal system can also be encountered.
  • These manifestations may cause a delay in the diagnosis of leukemia.
  • This case is presented to draw attention to the fact that leukemia must be considered in pediatric patients who present with bone manifestations.
  • [MeSH-major] Bone Diseases, Metabolic / etiology. Fractures, Spontaneous / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Radius Fractures / etiology
  • [MeSH-minor] Child. Delayed Diagnosis. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21434546.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


35. Ratei R, Karawajew L, Lacombe F, Jagoda K, Del Poeta G, Kraan J, De Santiago M, Kappelmayer J, Björklund E, Ludwig WD, Gratama JW, Orfao A, European Working Group of Clinical Cell Analysis: Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping. Leukemia; 2007 Jun;21(6):1204-11
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discriminant function analysis as decision support system for the diagnosis of acute leukemia with a minimal four color screening panel and multiparameter flow cytometry immunophenotyping.
  • Despite several recommendations for standardization of multiparameter flow cytometry (MFC) the number, specificity and combinations of reagents used by diagnostic laboratories for the diagnosis and classification of acute leukemias (AL) are still very diverse.
  • We determined the potential value of a minimal four-color combination panel of 13 monoclonal antibodies (mAbs) with a CD45/sideward light scatter-gating strategy for a standardized MFC immunophenotyping of the clinically most relevant subgroups of AL.
  • Bone marrow samples from 155 patients with acute myeloid leukemia (AML, n=79), B-cell precursor acute lymphoblastic leukemia (BCP-ALL, n=29), T-cell precursor acute lymphoblastic leukemia (T-ALL, n=12) and normal bone marrow donors (NBMD, n=35) were analyzed.
  • A knowledge-based learning algorithm was generated by comparing the results of the minimal panel with the actual diagnosis, using discriminative function analysis.
  • [MeSH-major] Diagnosis, Computer-Assisted / methods. Flow Cytometry / methods. Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Algorithms. Antibodies, Monoclonal. Bone Marrow / pathology. Cell Lineage. Color. Humans. Immunophenotyping. Reference Standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410192.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal
  •  go-up   go-down


36. Ziegler S, Sperr WR, Knöbl P, Lehr S, Weltermann A, Jäger U, Valent P, Lechner K: Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis. Thromb Res; 2005;115(1-2):59-64
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.
  • No systematic study on the incidence and prognostic impact of venous thromboembolism in acute leukemia has been performed as yet.
  • We retrospectively evaluated the incidence of symptomatic venous thromboembolism before chemotherapy in 719 patients (371 males and 348 females, median age of 57.4 years), diagnosed with acute leukemia [534 with acute myelogenous leukemia, 185 with acute lymphoblastic leukemia].
  • Fifteen patients (2.09%) had venous thromboembolism (objectively confirmed in 13 patients) in close temporal relationship to the onset of acute leukemia.
  • The incidence of venous thromboembolism was the same in acute myelogenous and lymphoblastic leukemia.
  • Venous thromboembolism occurred in all subtypes of acute leukemia, but was most common in promyelocytic leukemia.
  • Overall, survival, disease-free survival, and remission duration did not differ between the patient groups with and without venous thromboembolism.
  • In contrast to solid tumors, venous thromboembolism before or at diagnosis of acute leukemia is not associated with poor prognosis.
  • [MeSH-major] Leukemia / complications. Thromboembolism / etiology. Venous Thrombosis / etiology
  • [MeSH-minor] Acute Disease. Anticoagulants / therapeutic use. Antineoplastic Agents / therapeutic use. Female. Humans. Incidence. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / etiology. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Prognosis. Remission Induction. Retrospective Studies. Risk Factors. Survival Analysis

  • MedlinePlus Health Information. consumer health - Deep Vein Thrombosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15567454.001).
  • [ISSN] 0049-3848
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; 0 / Antineoplastic Agents
  •  go-up   go-down


37. Mahmoud LA, Shamaa SS, Salem MA, Aladle DA, Goda EF: A study for evaluation of different diagnostic approaches in acute leukemia in Egypt. Hematology; 2006 Apr;11(2):87-95
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A study for evaluation of different diagnostic approaches in acute leukemia in Egypt.
  • Cytomorphology, cytochemistry, immunophenotyping, in addition to cytogenetic and molecular analyses have specific roles in the diagnosis and management of acute leukemias.
  • This work was designed as a comparative study of different available methods for diagnosis of acute leukemia.
  • The study comprised 47 cases with acute leukemia (21 cases with ALL and 26 cases with AML).
  • The results of the study revealed that careful examination of Romanowsky-stained peripheral blood and BM films is fundamental in the diagnosis of acute leukemias, and when considered together with clinical and hematological features, indicates which of the more specialized techniques are most likely to be useful.
  • The major role of cytochemistry was in the diagnosis of AML, while the major role of immunophenotyping was in the diagnosis of acute leukemia, which is not obviously myeloid.
  • Apart from identification of chromosomal abnormalities unique to specific subtypes of leukemia, cytogenetic analysis had a salient impact on anticipating the prognosis and treatment outcome in acute leukemias.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16753847.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Genetic Markers
  •  go-up   go-down


38. Iwasaki T, Sugisaki C, Nagata K, Takagi K, Takagi A, Kojima T, Ito M, Nakamura S, Naoe T, Murate T: Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia. Pathol Int; 2007 Oct;57(10):645-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia.
  • Wilms' tumor 1 (WT1) is a useful marker for the diagnosis of acute leukemia and myelodysplastic syndromes (MDS).
  • An increase of all three WT1 messages in high-grade MDS and acute leukemia was observed as compared with the normal control, whereas there was no significant difference in WT1 message between AA and RA, suggesting that WT1 message is not a good tool to discriminate AA and RA.
  • Positive immunostaining of WT1 was observed only in the portion of acute leukemia and overt leukemia (OL) transformed from MDS with a high WT1 message level, suggesting the relatively high detection threshold of WT1 protein with the immunostaining method.
  • [MeSH-major] Gene Expression Regulation. Leukemia, Myeloid, Acute / metabolism. Myelodysplastic Syndromes / metabolism. RNA, Messenger / metabolism. WT1 Proteins
  • [MeSH-minor] Adult. Aged. Anemia, Aplastic / genetics. Anemia, Aplastic / metabolism. Anemia, Aplastic / pathology. Anemia, Refractory, with Excess of Blasts / genetics. Anemia, Refractory, with Excess of Blasts / metabolism. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. RNA, Neoplasm / analysis


39. Eapen M, Rubinstein P, Zhang MJ, Camitta BM, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE: Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. J Clin Oncol; 2006 Jan 1;24(1):145-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months.
  • PURPOSE: To describe outcomes after unrelated donor stem cell transplantation (HCT) in children (< 18 months at diagnosis) with acute leukemia and compare these with outcomes after human leukocyte antigen (HLA)-matched sibling donor HCT.
  • PATIENTS AND METHODS: We compared the results of unrelated donor HCT with bone marrow (n = 85) or cord blood grafts (n = 81) and HLA-matched sibling donor HCT with bone marrow grafts (n = 101) for acute myeloid or acute lymphoblastic leukemia using Cox proportional hazards models.
  • Unrelated donor HCT recipients were younger, more likely to have MLL gene rearrangement, to have advanced leukemia, and to receive irradiation before HCT.
  • Risks of relapse, overall and leukemia-free survival were significantly associated with disease status at transplantation.
  • Though leukemia recurrence was lowest after unrelated donor HCT in first clinical remission (CR), overall survival, and leukemia-free survival rates were similar after matched sibling and unrelated donor HCT, after adjustment for disease status.
  • Relapse, overall and leukemia-free survival did not differ by graft type (bone marrow v cord blood) or type of leukemia.
  • Three-year probabilities of leukemia-free survival were 49% and 54% after HLA-matched sibling and unrelated donor transplantation in first CR, respectively.
  • Corresponding rates for those with advanced leukemia were 20% and 30%.
  • CONCLUSION: Unrelated donor HCT should be considered for infants with acute leukemia in first CR using the same eligibility criteria as are currently used for those with HLA matched sibling donors.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Histocompatibility Testing. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Female. Graft vs Host Disease / epidemiology. Humans. Infant. Infant, Newborn. Male. Neutrophils / physiology. Platelet Count. Recurrence. Siblings. Survivors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16382124.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Lefèvre Y, Ceroni D, Läedermann A, de Rosa V, de Coulon G, Ayse HO, Kaelin A: Pediatric leukemia revealed by a limping episode: a report of four cases. Orthop Traumatol Surg Res; 2009 Feb;95(1):77-81
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric leukemia revealed by a limping episode: a report of four cases.
  • Acute limping in children is a common reason for consultation in pediatric emergency units.
  • Acute leukemia is a rarely encountered disease in the orthopedic surgeon's activity.
  • We report our experience with four cases of children initially seen in the pediatric emergency department for limping, as their revealing presentation of acute leukemia.
  • The physician in charge should remember that paraclinical work-up normal results do not exclude a diagnosis of acute leukemia, that any drop in hematopoietic cell counts should call for a myelogram and that paraclinical exams, including the hemogram, should be repeated until a diagnosis and improvement or confirmed cure is achieved over time.
  • [MeSH-major] Mobility Limitation. Pain / etiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251241.001).
  • [ISSN] 1877-0568
  • [Journal-full-title] Orthopaedics & traumatology, surgery & research : OTSR
  • [ISO-abbreviation] Orthop Traumatol Surg Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [General-notes] NLM/ Original DateCompleted: 20090708
  •  go-up   go-down


41. Bechtel K, Iragorri S: Hepatosplenomegaly and reticulocytopenia as prominent features of atypical hemolytic uremic syndrome. Pediatr Emerg Care; 2010 Jul;26(7):510-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This is a case of atypical hemolytic uremic syndrome (HUS) due to invasive pneumococcal disease in which the prominent clinical features were reticulocytopenia and hepatosplenomegaly, leading to the incorrect initial diagnosis of acute leukemia.
  • Delayed diagnosis of HUS, especially in atypical cases, can lead to increased morbidity and mortality.
  • Atypical HUS must be part of the differential diagnosis of children who present with clinical characteristics suggestive of a hematologic malignancy with associated renal injury.
  • [MeSH-major] Hemolytic-Uremic Syndrome / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Hepatomegaly. Humans. Infant. Peritoneal Dialysis. Reticulocytes. Splenomegaly


42. Pihan G: Detection of gene fusions in acute leukemia using bead microarrays. Curr Protoc Cytom; 2006 Feb;Chapter 13:Unit13.7
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of gene fusions in acute leukemia using bead microarrays.
  • This unit describes a method for the rapid and simultaneous detection of hybrid mRNAs (hRNA; also known as gene fusions, RNA fusions, or chimeric RNA), resulting from recurrent chromosome translocations or inversions in acute leukemia.
  • The principal components of the assay are a multiplex RT-PCR, which simultaneously amplifies any of a number of possible hRNA targets, and a liquid bead microarray (LBMA), which is capable of unambiguously identifying the amplified hRNA.
  • The assay is designed to detect the most common risk-stratifying translocation in pediatric acute lymphoblastic leukemia, satisfying the demand for inclusion of genetic data in the diagnosis of acute leukemia as predicated by the current WHO classification of hematopoietic and lymphoid neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18770837.001).
  • [ISSN] 1934-9300
  • [Journal-full-title] Current protocols in cytometry
  • [ISO-abbreviation] Curr Protoc Cytom
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


43. El-Ziny MA, Al-Tonbary YA, Salama OS, Bakr AA, Al-Marsafawy H, Elsharkawy AA: Low turnover bone disease in Egyptian children with acute leukemia. Hematology; 2005 Aug;10(4):327-33
Hazardous Substances Data Bank. CHOLECALCIFEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low turnover bone disease in Egyptian children with acute leukemia.
  • The aim of this work was to study bone turnover markers, calcium homeostasis and bone mineral density (BMD) in children with acute leukemia at diagnosis, after induction chemotherapy, and during maintenance therapy to delineate abnormalities present.
  • After evaluation of L2-L4 BMD using dual-energy X-ray absorptiometry in patients with acute myeloid and lymphoid leukemia at presentation and after treatment, the results were compared to 352 healthy age- and sex-matched Egyptian controls.
  • Osteopenia was observed at diagnosis and during treatment in patients with acute leukemia.
  • At diagnosis osteopenia was observed in 27 patients (62.8%): 10 (23.3%) had non severe osteopenia and 17 (39.5%) had severe osteopenia.
  • Parathyroid hormone (PTH) (pg/ml) levels demonstrated non significant differences between children with acute leukemia at different stages of therapy and controls, while, 25 (OH) D3 (ng/ml) was significantly lower in acute leukemia patients at different stages of therapy compared to controls (p<0.001).
  • Osteocalcin (ng/ml) is significantly lower in patients at different stages of the disease compared to controls (p<0.001) but there was no significant difference between patients at different stages of therapy.
  • Deoxy-pyridoline cross links showed non-significant difference between the different types of acute leukemia and with controls.
  • Osteopenia is a significant problem in children with acute leukemia at presentation and after chemotherapy.
  • Osteopenia in acute leukemia appears to be of the low turnover type (decreased osteoblastic activity and decreased bone mineralization).
  • [MeSH-major] Bone Density. Bone Diseases, Metabolic / blood. Bone Remodeling. Leukemia / blood
  • [MeSH-minor] Acute Disease. Adolescent. Child. Child, Preschool. Cholecalciferol / blood. Egypt. Humans. Infant. Male. Osteoblasts / metabolism. Osteocalcin / blood. Parathyroid Hormone / blood

  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16085546.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Parathyroid Hormone; 104982-03-8 / Osteocalcin; 1C6V77QF41 / Cholecalciferol
  •  go-up   go-down


44. Iguchi T, Yamada Y, Awaya N, Ikeda Y, Okamoto S, Kizaki M: Multilineage involvement of light microscopic myeloperoxidase-negative acute leukemia. Int J Hematol; 2005 Nov;82(4):315-8
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilineage involvement of light microscopic myeloperoxidase-negative acute leukemia.
  • The classification of acute leukemia has traditionally been based on a combination of morphology and cytochemical staining data, including myeloperoxidase (MPO) reaction; however, a recent World Health Organization (WHO) classification entails use of cytogenetic and molecular findings in addition to the classic morphological and immunophenotypic analyses.
  • These cases may be classified as acute leukemia of ambiguous lineage in the recent WHO classification.
  • We report the case of a 49-year-old man with acute leukemia with multilineage phenotypes.
  • Morphological findings led to a diagnosis of acute myeloid leukemia M2 by the French-American-British classification, but at light microscopy the results of MPO staining were negative for blast cells.
  • In contrast, results of reverse transcription polymerase chain reaction and fluorescence-activated cell sorter analyses were positive for expression of MPO messenger RNA and protein.
  • The blast cells expressed CD4, CD19, CD22, CD33, CD38, CD79a, and HLA-DR and showed rearrangement of the immunoglobulin heavy chain and TCR-3 genes.
  • Results of immunoelectron microscopic analysis of the blast cells were positive for MPO, CD19, CD33, CD34, CD38 and glycophorin A but not for platelet peroxidase.
  • According to these results, the blast cells had at least 4 lineage phenotypes.
  • We concluded that the multiparameter analyses conducted in this case, including immunological and ultrastructural assays, were important in arriving at the appropriate diagnosis of acute leukemia of ambiguous lineage in the new WHO classification.
  • [MeSH-major] Bone Marrow Cells / pathology. Leukemia / pathology. Peroxidase / genetics
  • [MeSH-minor] Acute Disease. Antigens, CD / analysis. Antigens, CD / genetics. Gene Rearrangement. HLA-DR Antigens / analysis. HLA-DR Antigens / genetics. Humans. Immunophenotyping. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298822.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / HLA-DR Antigens; EC 1.11.1.7 / Peroxidase
  •  go-up   go-down


45. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY: Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood; 2006 Apr 15;107(8):3065-73
Hazardous Substances Data Bank. BUSULFAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.
  • The outcomes of 293 patients with leukemia undergoing HLA-identical sibling (n = 158) or related HLA-mismatched (n = 135) hematopoietic cell transplantation (HCT) performed during the same time period were compared.
  • The cumulative incidences of grades II to IV acute graft-versus-host disease (aGVHD) in the matched and mismatched cohorts were 32% (CI, 25%-39%) versus 40% (CI, 32%-48%, P = .13), respectively, with the relative risk (RR) = 0.64 (95% CI, 0.43-0.94), P = .02.
  • Two-year adjusted leukemia-free survival (LFS) and overall survival were 71% (range, 63%-78%) versus 64% (range, 54%-73%) with P = .27 and 72% (range, 64%-79%) versus 71% (range, 62%-77%) with P = .72, respectively.
  • Multivariate analyses showed that only advanced disease stage and a diagnosis of acute leukemia had increased risk of relapse, treatment failure, and overall mortality.
  • [MeSH-major] Antilymphocyte Serum / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Immunosuppressive Agents / administration & dosage. Leukemia / therapy. Living Donors. Transplantation Conditioning
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Busulfan / administration & dosage. Child. Child, Preschool. Chronic Disease. Cohort Studies. Cyclophosphamide / administration & dosage. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / mortality. HLA Antigens. Histocompatibility. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging / methods. Recurrence. Severity of Illness Index. Transplantation, Homologous. Treatment Failure


46. Michallet AS, Nicolini F, Fürst S, Le QH, Dubois V, Hayette S, Bourgeot JP, Tremisi JP, Thomas X, Gebuhrer L, Michallet M: Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT). Bone Marrow Transplant; 2005 Mar;35(6):601-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
  • In order to study efficacy, toxicity and the long-term results of donor lymphocyte infusions (DLI), we retrospectively analyzed DLI given for relapse after conventional allogeneic hematopoietic stem cell transplantation (HSCT) in 30 patients with a median delay of 107.5 months after transplant and 58 months after DLI.
  • After DLI, 15 patients established full donor chimerism, three patients developed grade III and one grade IV acute GVHD.
  • A total of 15 patients achieved a disease response.
  • Among the 14 patients with chronic myeloid leukemia (CML), 11 are alive at the last follow-up: five are in complete molecular response (CMR) and two in complete cytogenetic response (CCR) with no other intervention after DLI, three in CMR after imatinib mesylate given after DLI and one in complete hematological response after imatinib mesylate and reduced-intensity conditioning allogeneic SCT performed after DLI.
  • The 3-year probability of survival for the entire population, CML patients and non-CML patients, was 60, 93, 62% after transplantation, and 48, 80 and 48% after DLI, respectively.
  • A multivariate analysis demonstrated a significantly worse survival rate after transplantation for female recipients, advanced disease and acute leukemia before transplantation.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphocyte Transfusion
  • [MeSH-minor] Adolescent. Adult. Female. Follow-Up Studies. Graft vs Host Disease. Hematologic Neoplasms / complications. Hematologic Neoplasms / mortality. Hematologic Neoplasms / therapy. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Risk Factors. Survival Analysis. Transplantation Chimera. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15756285.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


47. Cheng H, Yang Y, Dai W, Tang C, Shi M, Feng G, Kang T, Su X, Zhao G: Acute leukemia presenting with blasts first found in the cerebrospinal fluid but not in the peripheral blood. J Clin Neurosci; 2010 Oct;17(10):1252-5
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia presenting with blasts first found in the cerebrospinal fluid but not in the peripheral blood.
  • Acute leukemia presenting with central nervous system (CNS) signs and symptoms is uncommon and prone to be misdiagnosed.
  • Here, we report nine patients with acute leukemia, including five patients with acute lymphoblastic leukemia (ALL) and four patients with acute myeloid leukemia (AML).
  • Bone marrow examination confirmed the presence of acute leukemia in these patients.
  • Seven patients died within 18months of diagnosis and two patients developed stable disease.
  • Our findings show a novel presenting feature of acute leukemia and highlight the importance of CSF cytology in the diagnosis of acute leukemia.
  • [MeSH-major] Leukemia / cerebrospinal fluid. Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Cranial Nerve Diseases / blood. Cranial Nerve Diseases / cerebrospinal fluid. Cranial Nerve Diseases / etiology. Female. Humans. Male. Retrospective Studies. Spinal Cord / pathology. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20605098.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


48. Lamet S, Bracke A, Geluykens E, Vlieghe E, Seymons K, Gadisseur AP, Vrelust I, Van Marck V, Somville J, Lambert J: Medical and surgical management of paraneoplastic pyoderma gangrenosum--a case report and review of the literature. Acta Clin Belg; 2010 Jan-Feb;65(1):37-40
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a 44-year-old male with pyoderma gangrenosum (PG) presenting simultaneously with diagnosis of acute leukemia.
  • His skin disease was stabilized with corticosteroids and most lesions cleared after chemotherapy-induced remission of the malignancy, but the largest lesion remained necrotic.
  • (1) PG presenting simultaneously with a haematologic malignancy (2) Relapse with atypical bullous lesions with return of the malignancy and (3) The use of surgical modalities in managing patients with PG, a disease notorious for surgical complications.
  • [MeSH-major] Leukemia, Myeloid, Acute / drug therapy. Paraneoplastic Syndromes / drug therapy. Paraneoplastic Syndromes / surgery. Pyoderma Gangrenosum / drug therapy. Pyoderma Gangrenosum / surgery
  • [MeSH-minor] Adult. Anti-Bacterial Agents / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Drug Therapy, Combination. Fatal Outcome. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male

  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20373596.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Glucocorticoids; 0 / Immunosuppressive Agents
  • [Number-of-references] 17
  •  go-up   go-down


49. Panovska-Stavridis I, Ivanovski M, Hadzi-Pecova L, Ljatifi A, Trajkov D, Spiroski M, Cevreska L: A case report of aggressive adult neuroblastoma mimicking acute leukemia with fulminant course and fatal outcome. Prilozi; 2010;31(1):349-59
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of aggressive adult neuroblastoma mimicking acute leukemia with fulminant course and fatal outcome.
  • A case of aggressive adult neuroblastoma mimicking acute leukemia with fulminant course and fatal outcome is described.
  • Pancytopenia and circulating blasts cells at presentation suggested the diagnosis of acute leukemia in the previously healthy 38 years old Caucasian male patient, but flow-cytometry analysis of the bone marrow disclosed the correct diagnosis of neuroblastoma.
  • Subsequently, the diagnosis was confirmed by immunohistochemical staining of a bone marrow biopsy.
  • A review of the reported cases of neuroblastoma with leukemic features showed that several of them were misdiagnosed as having leukemia and that the diagnosis of neuroblastoma was made at autopsy examination, indicating that misdiagnosis may happen more often than is appreciated.
  • It is in our opinion that the diagnosis of neuroblastoma should be considered in all cases of acute leukemia and pancytopenia, regardless of the age group of the patients.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693952.001).
  • [ISSN] 0351-3254
  • [Journal-full-title] Prilozi
  • [ISO-abbreviation] Prilozi
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


50. Kim SR, Kim HJ, Kim SH: [Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia]. Korean J Lab Med; 2009 Oct;29(5):371-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia].
  • BACKGROUND: Cytogenetic abnormalities are one of the most reliable prognostic factors in acute leukemia.
  • The objective of this study was to investigate the utility of FISH profile analyses in the initial diagnosis of acute leukemia.
  • METHODS: Two hundred and forty one de novo acute leukemia patients diagnosed from January, 2002 to November, 2007 were included.
  • For acute lymphoblastic leukemia profile test, FISH probes for BCR/ABL, TEL/AML1, MLL gene rearrangement and CDKN2A deletion were used.
  • For acute myeloid leukemia profile test, probes for AML1/ETO, MLL and CBFbeta gene rearrangement were used.
  • RESULTS: ALL FISH profile tests revealed additional genetic aberrations not detected by chromosome analysis in 48.6% (67/138) of cases, including those with normal karyotypes or no mitotic cells (37%, 51/138).
  • CONCLUSIONS: FISH analysis as a profile test detected additional genetic aberrations in a significant proportion of acute leukemia, and was effective especially in detecting cryptic translocations, submicroscopic deletions and complex karyotypes.
  • Our study supports the need to incorporate FISH profile test at initial work up in acute leukemia.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor beta Subunit / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Humans. Infant. Infant, Newborn. Karyotyping. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Proto-Oncogene Proteins c-bcr / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893343.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RUNX1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


51. Ramirez LY, Huestis SE, Yap TY, Zyzanski S, Drotar D, Kodish E: Potential chemotherapy side effects: what do oncologists tell parents? Pediatr Blood Cancer; 2009 Apr;52(4):497-502
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to determine the number of short-term side effects and late effects discussed during an informed consent conference (ICC) after the diagnosis of acute leukemia, we observed the occurrence(s) and the ratio between short-term side effects versus late effects during an ICC.
  • PROCEDURE: ICC(s) of childhood leukemia trials were audio-taped at six different study sites.
  • RESULTS: One hundred forty cases were reviewed, from which we coded a total of 3,173 acute side effects and 242 late effects.
  • The number of late effects coded were significantly less than acute side effects.
  • CONCLUSIONS: Our results show that acute side effects are often mentioned but the discussion of late effects is much less frequent in the initial ICC(s).
  • Careful consideration regarding the ratio of acute and late effects that are communicated to parents in the context of the ICC may facilitate parental understanding of clinically relevant side effects.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 Wiley-Liss, Inc.
  • [Cites] Am J Dis Child. 1984 Jul;138(7):649-53 [6587772.001]
  • [Cites] Lancet. 2001 Mar 3;357(9257):670-4 [11247550.001]
  • [Cites] Arch Intern Med. 2001 Mar 12;161(5):706-13 [11231703.001]
  • [Cites] Lancet Oncol. 2002 Oct;3(10):629-37 [12372725.001]
  • [Cites] JAMA. 2004 Jan 28;291(4):470-5 [14747504.001]
  • [Cites] J Med Ethics. 2007 Feb;33(2):67-70 [17264190.001]
  • [Cites] Palliat Med. 1994;8(2):105-14 [8081551.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):891-7 [16484698.001]
  • [Cites] Pediatr Blood Cancer. 2006 Nov;47(6):819-24 [16615062.001]
  • [Cites] Recent Results Cancer Res. 2006;168:105-12 [17073196.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):23-31 [17224658.001]
  • [CommentIn] Pediatr Blood Cancer. 2009 Apr;52(4):437-8 [19058206.001]
  • (PMID = 19101994.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA083267-08; United States / NCI NIH HHS / CA / R01 CA083267; United States / NCI NIH HHS / CA / R01 CA083267-08; United States / NCI NIH HHS / CA / R01 CA83267
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS83695; NLM/ PMC2643320
  •  go-up   go-down


52. Wang ZY, Chen QS: [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Apr;13(2):169-73
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Present status in studying immunotherapy for acute leukemia and its perspective--Editorial].
  • One of the important approaches for further prolonging remission duration and eradicating minimal residual disease in acute leukemia is immunotherapy.
  • Four kinds of immunotherapy for acute leukemia are under investigation:.
  • (1) monoclonal antibodies, among them, Mylotarg (cytotoxic antibiotic calicheamicin linked to CD33 Mab) is given for the treatment of refractory or relapsed acute myeloid leukemia and molecular relapse in acute promyelocytic leukemia with good results, Campath-1H (antiCD52 Mab) is administered in the treatment of prolymphocytic leukemia and Rituximab (anti-CD20 Mab) in B-PLL with high complete remission rates.
  • Other Mabs under preclinical and clinical trials include anti-IL-2 receptor Mab for the treatment of acute T lymphocytic leukemia, anti-220 kD Mab-6G7 for acute leukemias, recombinant immune toxin BL22 (anti-CD22) for hairy cell leukemia and Mabs labeled with radio-isotopes for different types of acute leukemias;.
  • (2) adoptive cellular immunotherapy using cytokine-induced killer cell, alloreactive NK cells, allogeneic or autologous leukemic-specific CD8(+) cytotoxic T lymphocytes, and other immune effector cells;.
  • (4) leukemia vaccines of several different formulations including antigen-specific, leukemia cell-based, leukemia antigen-pulsed dendritic cell (DC) and leukemia-derived DC vaccines, the latter two formulations are more attractive.
  • In conclusion, up to now, the most effective example of immunotherapy in acute leukemia is provided by the administration of Mabs, and the majority of other approaches in immunotherapy for acute leukemia although promising, need further studies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854271.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines
  •  go-up   go-down


53. Deconinck E, Hunault M, Milpied N, Bernard M, Renaud M, Desablens B, Delain M, Witz F, Lioure B, Pignon B, Guyotat D, Berthou C, Jouet JP, Casassus P, Ifrah N, Boiron JM: Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study. Biol Blood Marrow Transplant; 2005 Jun;11(6):448-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive therapy before or during the conditioning regimen of allogeneic marrow transplantation in adult acute lymphoblastic leukemia patients: we must choose to reduce Toxicity--a Groupe Ouest-Est d'Etude des Leucemies et Autres Maladies du Sang study.
  • To improve the results in the treatment of adult acute lymphoblastic leukemia patients, different strategies have been proposed.
  • The Leucemie Aigue Lymphoblastique Paris-Ouest-France (LALPOF) protocol proposed alloBMT with standard conditioning after a classic induction and intensified consolidation scheme; the Groupe Ouest Est des Leucemies Aigues Lymphoblastiques (GOLEAL1) protocol tested an intensified induction and consolidation course before alloBMT with a reinforced conditioning regimen.
  • The 4-year disease-free survival reached 75% +/- 11% in the LALPOF study and 69% +/- 13% in the GOELAL1 study ( P = .30).
  • For adult acute lymphoblastic leukemia patients in first remission, the intensification of chemotherapy before a reinforced conditioning regimen before alloBMT may lead to an increased toxic death rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation Conditioning


54. Bies J, Sramko M, Fares J, Rosu-Myles M, Zhang S, Koller R, Wolff L: Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia. Blood; 2010 Aug 12;116(6):979-87
SciCrunch. Marmoset Gene list: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid-specific inactivation of p15Ink4b results in monocytosis and predisposition to myeloid leukemia.
  • Inactivation of p15INK4b, an inhibitor of cyclin-dependent kinases, through DNA methylation is one of the most common epigenetic abnormalities in myeloid leukemia.
  • Although this suggests a key role for this protein in myeloid disease suppression, experimental evidence to support this has not been reported.
  • To address whether this event is critical for premalignant myeloid disorders and leukemia development, mice were generated that have loss of p15Ink4b specifically in myeloid cells.
  • The p15Ink4b(fl/fl)-LysMcre mice develop nonreactive monocytosis in the peripheral blood accompanied by increased numbers of myeloid and monocytic cells in the bone marrow resembling the myeloproliferative form of chronic myelomonocytic leukemia.
  • Spontaneous progression from chronic disease to acute leukemia was not observed.
  • Nevertheless, MOL4070LTR retrovirus integrations provided cooperative genetic mutations resulting in a high frequency of myeloid leukemia in knockout mice.
  • Two common retrovirus insertion sites near c-myb and Sox4 genes were identified, and their transcript up-regulated in leukemia, suggesting a collaborative role of their protein products with p15Ink4b-deficiency in promoting malignant disease.
  • This new animal model demonstrates experimentally that p15Ink4b is a tumor suppressor for myeloid leukemia, and its loss may play an active role in the establishment of preleukemic conditions.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Transgenic Res. 1999 Aug;8(4):265-77 [10621974.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1251-61 [17452517.001]
  • [Cites] Br J Haematol. 2001 Jan;112(1):148-54 [11167795.001]
  • [Cites] Methods Mol Biol. 2001;158:47-63 [11236671.001]
  • [Cites] Best Pract Res Clin Haematol. 2001 Mar;14(1):49-64 [11355923.001]
  • [Cites] Biochim Biophys Acta. 2002 Mar 14;1602(1):73-87 [11960696.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Blood. 2002 Jul 1;100(1):246-58 [12070034.001]
  • [Cites] Nature. 2007 Aug 23;448(7156):943-6 [17713536.001]
  • [Cites] Leukemia. 2009 Jan;23(1):85-94 [18818702.001]
  • [Cites] Br J Cancer. 2009 Feb 10;100(3):511-23 [19156145.001]
  • [Cites] Cell Stem Cell. 2009 Feb 6;4(2):129-40 [19200802.001]
  • [Cites] Hum Mol Genet. 2009 Apr 1;18(7):1343-52 [19153074.001]
  • [Cites] J Neurooncol. 2002 May;57(3):201-14 [12125983.001]
  • [Cites] Nat Rev Cancer. 2003 Feb;3(2):89-101 [12563308.001]
  • [Cites] J Virol. 2003 Apr;77(8):4965-71 [12663802.001]
  • [Cites] Leukemia. 2003 May;17(5):910-8 [12750705.001]
  • [Cites] Oncogene. 2003 Dec 18;22(58):9265-74 [14681685.001]
  • [Cites] Oncogene. 1989 May;4(5):583-92 [2471131.001]
  • [Cites] Mol Cell Biol. 1992 Jun;12(6):2493-500 [1588953.001]
  • [Cites] Virology. 1994 Dec;205(2):479-85 [7975249.001]
  • [Cites] Cell Growth Differ. 1995 Jan;6(1):59-68 [7536440.001]
  • [Cites] Nature. 1996 Apr 25;380(6576):711-4 [8614465.001]
  • [Cites] Cancer Res. 1996 Feb 15;56(4):722-7 [8631003.001]
  • [Cites] Virology. 1996 Oct 1;224(1):224-34 [8862417.001]
  • [Cites] Blood. 1997 Aug 15;90(4):1403-9 [9269757.001]
  • [Cites] Leukemia. 1998 Jun;12(6):845-59 [9639410.001]
  • [Cites] J Natl Cancer Inst. 1999 Jan 6;91(1):73-9 [9890173.001]
  • [Cites] J Virol. 1999 Mar;73(3):2038-44 [9971784.001]
  • [Cites] Oncogene. 1999 May 13;18(19):3017-33 [10378697.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2445-51 [10498617.001]
  • [Cites] Leuk Res. 2005 Jun;29(6):653-9 [15863205.001]
  • [Cites] Am J Clin Pathol. 2005 Nov;124(5):799-806 [16203279.001]
  • [Cites] Eur J Haematol. 2006 Jan;76(1):23-32 [16343268.001]
  • [Cites] Blood. 2006 Jan 15;107(2):733-41 [16204320.001]
  • [Cites] Br J Dermatol. 2006 Nov;155(5):999-1005 [17034532.001]
  • [Cites] Exp Hematol. 2007 Mar;35(3):394-406 [17309820.001]
  • [Cites] Nat Genet. 2007 May;39(5):593-5 [17435759.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]
  • [Cites] EMBO J. 2000 Jul 3;19(13):3496-506 [10880462.001]
  • (PMID = 20457873.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2b protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / SOXC Transcription Factors; 0 / Sox4 protein, mouse
  • [Other-IDs] NLM/ PMC2924230
  •  go-up   go-down


55. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP: Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Biol Blood Marrow Transplant; 2009 Feb;15(2):257-65
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains one of the best therapeutic options to cure acute leukemia (AL).
  • Recently, we developed a new method for HLA-mismatched/haploidentical transplantation without in vitro T cell depletion (TCD).
  • The incidence of grade 2-4 acute graft-versus-host disease (aGVHD) was 45.8%, and that of grades 3 and 4 was 13.4%, which was not associated with the extent of HLA disparity.
  • One hundred forty-one of the 250 patients survived free of disease recurrence at a median of 1092 days (range: 442-2437 days) of follow-up.
  • Seventeen patients received DLI as a treatment for relapse after transplantation and 7 patients achieved leukemia-free survival (LFS).
  • The 3-year probability of LFS for acute myelogenous leukemia (AML) was 70.7% and 55.9%, and for acute lymphoblastic leukemia (ALL) it was 59.7% and 24.8% in standard-risk and high-risk groups, respectively.
  • Lower LFS were associated with diagnosis of acute leukemia in the high-risk group (P= .001, relative risk [RR], 95% confidence interval [CI]: 2.94[1.535-5.631]) and the occurrence of aGVHD of grades 3 and 4 (P= .004).
  • [MeSH-major] Bone Marrow Transplantation / methods. HLA Antigens / immunology. Haplotypes / immunology. Histocompatibility / immunology. Leukemia / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Host Disease / immunology. HLA-A Antigens. HLA-B Antigens. HLA-DR Antigens. Humans. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / therapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Transplantation, Homologous / immunology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19167686.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens; 0 / HLA-A Antigens; 0 / HLA-B Antigens; 0 / HLA-DR Antigens
  •  go-up   go-down


56. Thakkar SG, Fu AZ, Sweetenham JW, Mciver ZA, Mohan SR, Ramsingh G, Advani AS, Sobecks R, Rybicki L, Kalaycio M, Sekeres MA: Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit. Cancer; 2008 May 15;112(10):2233-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival and predictors of outcome in patients with acute leukemia admitted to the intensive care unit.
  • BACKGROUND: Predictors of outcome and rates of successful discharge have not been defined for patients with acute leukemia admitted to intensive care units (ICUs) in the US.
  • METHODS: This is a retrospective analysis of 90 patients with acute leukemia (no history of bone marrow transplant) admitted to an ICU from 2001-2004.
  • During the ICU course, 29 patients (32%) improved and subsequently resumed aggressive leukemia management, and 24 patients (27%) survived to be discharged from the hospital.
  • Newly diagnosed leukemia, type of leukemia, or age did not.
  • CONCLUSIONS: One of 4 patients with acute leukemia survived an ICU admission to be discharged from the hospital and were alive 2 months later.
  • A diagnosis of acute leukemia should not disqualify patients from an ICU admission.
  • [MeSH-major] Hospital Mortality. Intensive Care Units. Leukemia, Myeloid, Acute / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18348307.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Chandrasekar P: Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation. Med Mycol; 2009;47 Suppl 1:S349-54
MedlinePlus Health Information. consumer health - Aspergillosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prophylaxis against Aspergillus is not perfect: problems and perils in stem cell transplantation.
  • Availability of newer, well tolerated anti-Aspergillus drugs at a time of rising prevalence of invasive aspergillosis has sparked enthusiasm for chemoprophylaxis against Aspergillus in allogeneic stem cell recipients.
  • Posaconazole, approved for prophylaxis in allogeneic stem cell recipients with graft versus host disease and in those with acute leukemia, is of promise but has a limitation relating to its oral bioavailability.
  • [MeSH-major] Aspergillosis / prevention & control. Chemoprevention / methods. Stem Cell Transplantation / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18663660.001).
  • [ISSN] 1460-2709
  • [Journal-full-title] Medical mycology
  • [ISO-abbreviation] Med. Mycol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 33
  •  go-up   go-down


58. Rondón G, Saliba RM, Khouri I, Giralt S, Chan K, Jabbour E, McMannis J, Champlin R, Shpall E: Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis. Biol Blood Marrow Transplant; 2008 Aug;14(8):859-66
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis.
  • The long-term outcome of graft failure after allogeneic stem cell transplantation (SCT) has not been well described.
  • Cases were included for analysis if they had failed to achieve an absolute neutrophil count (ANC) of 500/microL or more by 28 days post-SCT or 42 days after cord blood transplantation (primary graft failure); had a decrease in their ANC to <500/mL for 3 consecutive days after having achieved neutrophil engraftment (secondary graft failure); or failed to have evidence of at least 5% or more donor cell engraftment (primary graft failure with autologous reconstitution).
  • A diagnosis of acute leukemia was a significant predictor for poor survival on multivariate analysis.
  • [MeSH-major] Graft Rejection / etiology. Hematopoietic Stem Cell Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18640568.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS712198; NLM/ PMC4548938
  •  go-up   go-down


59. Mullighan CG: Genomic analysis of acute leukemia. Int J Lab Hematol; 2009 Aug;31(4):384-97
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic analysis of acute leukemia.
  • Acute leukemia is the commonest childhood cancer and a major cause of morbidity from hematologic malignancies in adults.
  • Acute lymphoblastic leukemia (ALL) is commonest in children, and acute myeloid leukemia (AML) is more frequent in adults.
  • Apart from childhood ALL, the prognosis of acute leukemia is suboptimal, with many patients experiencing relapse, which carries a poor prognosis, or toxicities from nonspecific therapies.
  • Recent years have witnessed great interest in the application of high-resolution, genome wide approaches to the study of acute leukemia.
  • These studies have identified multiple novel genetic alterations targeting critical cellular pathways that contribute to leukemogenesis, including alterations of genes regulating lymphoid development, tumor suppressors, apoptosis regulators, and oncogenes.
  • These studies have also delineated novel genetic alterations that are associated with prognosis, and have demonstrated substantial evolution in patterns of genetic alterations from diagnosis to relapse, indicating that specific genetic changes determine resistance to therapy in ALL.
  • These studies have demonstrated the power of genome-wide approaches to identify new lesions in acute leukemia, and suggest that ongoing genomic analyses, including deep resequencing and epigenetic analysis, will continue to yield novel, clinically relevant insights into the pathogenesis of this disease.
  • [MeSH-major] Leukemia, Myeloid, Acute / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486196.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 112
  •  go-up   go-down


60. Gujral S, Polampalli S, Badrinath Y, Kumar A, Subramanian PG, Raje G, Amare P, Arora B, Banavali SD, Nair CN: Clinico-hematological profile in biphenotypic acute leukemia. Indian J Cancer; 2009 Apr-Jun;46(2):160-8
Genetic Alliance. consumer health - Acute Biphenotypic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-hematological profile in biphenotypic acute leukemia.
  • BACKGROUND: We present a clinico-hematological profile and treatment outcome of Biphenotypic Acute Leukemia (BAL).
  • AIM: Study incidence and subtypes of BAL, correlate with age, morphology, and cytogenetic findings and correlate the clinico-hematological data with the treatment response.
  • MATERIAL AND METHODS: Diagnosis was based on WHO classification, including clinical details, morphology, cytochemistry, immunophenotyping, and molecular genetics.
  • We included those cases, which fulfilled the European Group for the Immunological Characterization of Acute Leukemia's (EGIL's) scoring system criteria for the diagnosis of BAL, as per recommendation of the WHO classification.
  • BCR ABL fusion positivity was a common cytogenetic abnormality (seven cases).
  • A comprehensive panel of reagents is required, including cytoplasmic markers; to diagnose BAL.
  • BCR-ABL expression is an important prognostic factor, as these cases will be labeled as Chronic myeloid leukemia (CML) in blast crisis with biphenotypic expression and treated accordingly.
  • [MeSH-major] Immunophenotyping. Leukemia, Biphenotypic, Acute / blood. Leukemia, Biphenotypic, Acute / diagnosis
  • [MeSH-minor] Adolescent. Adult. Case-Control Studies. Child. Child, Preschool. Disease Progression. Female. Hematologic Tests. Humans. Incidence. Male. Middle Aged. Phenotype. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19346652.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


61. Emerenciano M, Koifman S, Pombo-de-Oliveira MS: Acute leukemia in early childhood. Braz J Med Biol Res; 2007 Jun;40(6):749-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute leukemia in early childhood.
  • Acute leukemia in early childhood is biologically and clinically distinct.
  • The particular characteristics of this malignancy diagnosed during the first months of life have provided remarkable insights into the etiology of the disease.
  • The pro-B, CD10 negative immunophenotype is typically found in infant acute leukemia, and the most common genetic alterations are the rearrangements of the MLL gene.
  • The Brazilian Collaborative Study Group of Infant Acute Leukemia has found that mothers exposed to dipyrone, pesticides and hormones had an increased chance to give birth to babies with infant acute leukemia [OR = 1.48 (95%CI = 1.05-2.07), OR = 2.27 (95%CI = 1.56-3.31) and OR = 9.08 (95%CI = 2.95-27.96)], respectively.
  • This review aims to summarize recent clues that have facilitated the elucidation of the biology of early childhood leukemias, with emphasis on infant acute leukemia in the Brazilian population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17581672.001).
  • [ISSN] 0100-879X
  • [Journal-full-title] Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas
  • [ISO-abbreviation] Braz. J. Med. Biol. Res.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 60
  •  go-up   go-down


62. Gong H, Liu W, Zhou J, Xu H: Methylation of gene CHFR promoter in acute leukemia cells. J Huazhong Univ Sci Technolog Med Sci; 2005;25(3):240-2
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation of gene CHFR promoter in acute leukemia cells.
  • In order to explore whether gene CHFR was inactivated by methylation in leukemia cells, the expression of CHFR was examined before and after treatment with demethylation agent in Molt-4, Jurkat and U937 leukemia cell lines by means of RT-PCR.
  • The methylation of promoter in Molt-4, Jurkat and U937 cells as well as 41 acute leukemia patients was analyzed by MS-PCR.
  • CHFR promoter methylation was detected in 39% of acute leukemia patients.
  • There was no difference in incidence of CHFR promoter methylation between acute myelocytic leukemia and acute lymphocytic leukemia.
  • In conclusion, CHFR is frequently inactivated in acute leukemia and is a good candidate for the leukemia supper gene.
  • By affecting mitotic checkpoint function, CHFR inactivation likely plays a key role in tumorigenesis in acute leukemia.
  • Moreover, the methylation of gene CHFR appears to be a good index with which to predict the sensitivity of acute leukemia to microtubule inhibitors.
  • [MeSH-major] Cell Cycle Proteins / genetics. DNA Methylation. Leukemia, Myeloid, Acute / genetics. Neoplasm Proteins / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Promoter Regions, Genetic / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16201259.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CHFR protein, human; 0 / Cell Cycle Proteins; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  •  go-up   go-down


63. Harani MS, Adil SN, Shaikh MU, Kakepoto GN, Khurshid M: Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi. J Ayub Med Coll Abbottabad; 2005 Jan-Mar;17(1):26-9
Genetic Alliance. consumer health - Leukemia, Myeloid.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of fab subtypes in acute myeloid leukemia patients at Aga Khan University Hospital Karachi.
  • BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease.
  • Therefore, various parameters are needed to classify this disease into subtypes, so that specific treatment approaches can be utilized effectively.
  • The commonly used method for diagnosis and classification is based on FAB criteria using morphology and cytochemical stains.
  • The aim of present study is to determine the frequency of various sub types in acute myeloid leukemia using FAB criteria in our population.
  • This will aid in the correct diagnosis of acute leukemia and hence proper management of the patients.
  • The patients were diagnosed on the basis of bone marrow morphology using FAB classification.
  • CONCLUSIONS: The most common FAB subtype observed in our study was Acute myelomonocytic leukemia (M4) which is in accordance with studies reported from Saudia Arabia and a previous study reported from our institution.
  • However,other national and international studies have reported Myeloblastic Leukemia with maturation (M2) as the predominant subtype of AML.
  • [MeSH-major] Leukemia, Myeloid / classification
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Case-Control Studies. Child. Child, Preschool. Female. Hospitals, University. Humans. Infant. Male. Middle Aged. Pakistan

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929522.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


64. Azghari A, Boukhbrine MK, Tijani Y, Bouziane Z, Idrissi R, Lekehal B, Sefiani Y, El Mesnaoui A, Boayad M, Ammar F, Bensaid Y: [Acute lower limb ischemia revealing acute leukemia. Case report and review of the literature]. J Mal Vasc; 2010 Feb;35(1):43-6
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute lower limb ischemia revealing acute leukemia. Case report and review of the literature].
  • [Transliterated title] Ischémie aiguë du membre inférieur révélant une leucémie aiguë. A propos d'un cas et revue de la littérature.
  • Large vessel thrombosis is a very rare clinical presentation of acute leukemia which is usually revealed by hemorrhagic complications or thrombosis of small vessels.
  • We present here the case of a patient with previously undiagnosed acute myeloid leukemia who was referred to our hospital with symptoms of acute ischemia of the left lower limb.
  • [MeSH-major] Arterial Occlusive Diseases / etiology. Femoral Artery. Ischemia / etiology. Leg / blood supply. Leukemia, Promyelocytic, Acute / complications. Leukostasis / etiology. Popliteal Artery

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19962259.001).
  • [ISSN] 0398-0499
  • [Journal-full-title] Journal des maladies vasculaires
  • [ISO-abbreviation] J Mal Vasc
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5688UTC01R / Tretinoin; ZS7284E0ZP / Daunorubicin
  • [Number-of-references] 12
  •  go-up   go-down


65. Anand M, Sharma S, Kumar R, Raina V: Diagnostic considerations in prolymphocytes in pleural fluid: a case report. Acta Cytol; 2008 Mar-Apr;52(2):251-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prolymphocytes are nucleolated cells that are the defining features of the 2 chronic lymphoproliferative disorders, prolymphocytic leukemia (PLL) and chronic lymphocytic leukemia (CLL) with increased prolymphocytes.
  • Prolymphocytes appear relatively unfamiliar in cytopathology practice, and, particularly when present in body fluids, may resemble blasts or adult T-cell leukemia/ lymphoma (ATLL) cells.
  • CASE: A 32-year-old man, referred to us with a diagnosis of acute leukemia, presented with shortness of breath for 2 months and loss of appetite for 3 months.
  • Better awareness among cytopathologists about prolymphocytes and the disease states in which they occur, as well as insistence, in a clinical setting of leukemia, on interpreting the pleural fluid in relation to the clinical and laboratory findings, especially those of the peripheral blood and bone marrow, can prevent misdiagnosis.
  • [MeSH-major] Diagnostic Errors / prevention & control. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Leukemia, Prolymphocytic, T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Pleural Effusion, Malignant / pathology. Precursor Cells, T-Lymphoid / pathology

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18500006.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


66. Tsimberidou AM, Keating MJ: Richter syndrome: biology, incidence, and therapeutic strategies. Cancer; 2005 Jan 15;103(2):216-28
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Richter's transformation denotes the development of high-grade non-Hodgkin lymphoma, prolymphocytic leukemia, Hodgkin disease, or acute leukemia in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma.
  • Multiple genetic defects, such as mutations of the p53 tumor suppressor gene, p16INK4A, and p21, loss of p27 expression, deletion of retinoblastoma, increased copy number of C-MYC, and decreased expression of the A-MYB gene, have been described.
  • Therapeutic strategies include intensive chemotherapy, monoclonal antibodies, and stem cell transplantation.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Lymphocytic, Chronic, B-Cell / therapy. Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Prognosis. Risk Assessment. Severity of Illness Index. Stem Cell Transplantation / methods. Survival Analysis. Syndrome. Treatment Outcome

  • Genetic Alliance. consumer health - Richter syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society.
  • (PMID = 15578683.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 159
  •  go-up   go-down


67. Kaćanski N, Konstantinidis N, Kolarović J, Slavković B, Vujić D: [Biphenotypic acute leukaemia: case reports of two paediatric patients]. Med Pregl; 2010 Nov-Dec;63(11-12):867-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biphenotypic acute leukaemia: case reports of two paediatric patients].
  • INTRODUCTION: Biphenotypic acute leukaemia is an uncommon type of leukaemia whose blasts co-express myeloid and B-or T-lymphoid antigens.
  • CASE REPORT: We describe two cases of paediatric patients with biphenotypic acute leukaemia.
  • A four-year-old female patient was found to have myeloid and B-lymphoid associated antigens in the same blast cells.
  • Cytogenetic analysis showed a Philadelphia (Ph) positivity t (9;22) (q34;q1l1 with rearrangements of M.bcr-Abl (p210).
  • She was treated with combined acute myeloid leukaemia/acute lymphoblastic leukaemia induction therapy followed by autologous stem cell transplantation.
  • The patient died due to the complications of stem cell transplantation procedure.
  • Another patient was a 20-month-old girl with myeloid and T-lymphoid associated antigens in the blast cells and with normal karyotype.
  • She received acute myeloid leukaemia induction therapy.
  • DISCUSSION: Immunophenotype is essential to establish the diagnosis of biphenotypic acute leukaemia according to the scoring system adopted by the European Group of Immunological Classification of Leukaemia.
  • There is no agreement about uniformity in treatment for the patients with this type of leukaemia.
  • Biphenotypic acute leukaemia is a high risk leukaemia which requires a more intensive treatment.
  • CONCLUSION: Therapy for every patient with biphenotypic acute leukaemia should depend on their immunophenotype and gene rearrangement profiles.
  • [MeSH-major] Leukemia, Biphenotypic, Acute / diagnosis. Leukemia, Biphenotypic, Acute / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21553470.001).
  • [ISSN] 0025-8105
  • [Journal-full-title] Medicinski pregled
  • [ISO-abbreviation] Med. Pregl.
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


68. Migunova EV, Sakhibov IaD, Ryzhko VV, Sorokina OM, Sagdieva NSh, Gemdzhian EG: [The survival and sequestration of transfused donor platelets in cytostatic cytopenias]. Ter Arkh; 2010;82(12):51-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: To study the survival and sequestration of transfused donor platelets labeled with 51Cr in patients with acute leukemia (AL).
  • [MeSH-minor] Cell Survival. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21516740.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


69. Zhou RQ, Gong YP, Zheng BH, Yang X: [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Sep;41(5):789-92
Hazardous Substances Data Bank. DAUNORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effects of bortezomib combined with daunorubicin on proliferation and apoptosis in primary adult acute leukemia].
  • OBJECTIVE: To assess effects of proteasome inhibitor Bortezomib (Bor) in combination with Daunorubicin (DNR) on proliferation, apoptosis and the expression of Bcl-2 mRNA in primary leukemia cells in vitro.
  • METHODS: Primary leukemia cells were isolated from bone marrow of adult acute leukemia patients using Ficoll liquid, then the primary leukemia cells were treated with different concentration of these two drugs (Bor 5, 10, 20, 50 nmol/L, DNR 50, 100, 200, 500 nmol/L, and Bor 5, 10 nmol/L combined with DNR 50, 100, 200, 500 nmol/L respectively ).
  • RESULTS: Growth inhibition ratio of all the types of acute leukemia cells were increased with the treatment of DNR and Bor in dose-dependent manner.
  • CONCLUSION: Bor combined with DNR shows synergetic effect in promoting the apoptosis of adult acute leukemia primary cells as well as inhibitory effect on the proliferation of leukemia cells.
  • [MeSH-major] Apoptosis / drug effects. Boronic Acids / pharmacology. Daunorubicin / pharmacology. Leukemia, Myeloid, Acute / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Pyrazines / pharmacology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21302442.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


70. Jung S, Chae H, Lim J, Oh EJ, Kim Y, Park YJ, Han K: Differential blast counts obtained by automated blood cell analyzers. Korean J Lab Med; 2010 Dec;30(6):540-6
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential blast counts obtained by automated blood cell analyzers.
  • BACKGROUND: Automated blood cell analyzers often read leukemic blasts as normal cells.
  • In this study, we evaluated the 5-part differential patterns of blasts using automated analyzers to determine if they can differentiate among blast types.
  • METHODS: Blood samples containing 10% or more blasts were collected from patients with acute leukemia (N=175).
  • RESULTS: The DxH 800 reported the 5-part white blood cell differential count in 98.9% of the cases.
  • In 11 cases, the DxH 800 reported a 5-part differential count without a blast flag.
  • CONCLUSIONS: Some automated analyzers are able to recognize and count blasts according to their characteristic cell types.
  • Therefore, complete blood counts obtained automatically can provide valuable data for making provisional decisions regarding the lineage of leukemia cells before further investigation.
  • [MeSH-major] Blood Cell Count / instrumentation. Leukemia / diagnosis
  • [MeSH-minor] Acute Disease. Automation. Humans. Leukemia, Monocytic, Acute / blood. Leukemia, Monocytic, Acute / diagnosis. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Promyelocytic, Acute / blood. Leukemia, Promyelocytic, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Blood Count Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21157136.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  •  go-up   go-down


71. Zhao X, Wu Q, Fu X, Yu B, Shao Y, Yang H, Guan M, Huang X, Zhang W, Wan J: Examination of copy number variations of CHST9 in multiple types of hematologic malignancies. Cancer Genet Cytogenet; 2010 Dec;203(2):176-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A recent array-based study implicated the presence of copy-number variations (CNV) of the region encompassing CHST9 in the genomes of acute myelogenous leukemia.
  • We found significant association between the CNV of CHST9 and these hematologic malignancies including acute lymphoblastic leukemia, acute myelogenous leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, and myelodysplastic syndrome.
  • [MeSH-minor] Bone Marrow / pathology. Bone Marrow Cells / metabolism. China. Female. Gene Deletion. Humans. Leukemia, Myeloid, Acute / genetics. Male. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21156230.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.8.2.- / CHST9 protein, human; EC 2.8.2.- / Sulfotransferases
  •  go-up   go-down


72. Rudant J, Orsi L, Menegaux F, Petit A, Baruchel A, Bertrand Y, Lambilliotte A, Robert A, Michel G, Margueritte G, Tandonnet J, Mechinaud F, Bordigoni P, Hémon D, Clavel J: Childhood acute leukemia, early common infections, and allergy: The ESCALE Study. Am J Epidemiol; 2010 Nov 1;172(9):1015-27
MedlinePlus Health Information. consumer health - Allergy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood acute leukemia, early common infections, and allergy: The ESCALE Study.
  • This study investigated the role of factors considered related to early stimulation of the immune system in the etiology of childhood acute leukemia.
  • Included were 634 acute lymphoblastic leukemia cases, 86 acute myeloblastic leukemia cases, and 1,494 controls aged ≥1 year.
  • Negative associations were observed between acute lymphoblastic leukemia and birth order (P for trend < 0.0001), attendance at a day-care center before age 1 year (odds ratio (OR) = 0.8, 95% confidence interval (CI): 0.6, 1.1), prolonged breastfeeding (OR = 0.7, 95% CI: 0.5, 1.0), repeated early common infections (OR = 0.7, 95% CI: 0.6, 0.9), regular contact with farm animals (OR = 0.6, 95% CI: 0.5, 0.8), frequent farm visits in early life (OR = 0.4, 95% CI: 0.3, 0.6), and history of asthma (OR = 0.7, 95% CI: 0.4, 1.0) or eczema (OR = 0.7, 95% CI: 0.6, 0.9).
  • Results support the hypothesis that repeated early infections and asthma may play a role against childhood acute leukemia.
  • [MeSH-major] Hypersensitivity / epidemiology. Infection / epidemiology. Leukemia, Myeloid, Acute / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20807738.001).
  • [ISSN] 1476-6256
  • [Journal-full-title] American journal of epidemiology
  • [ISO-abbreviation] Am. J. Epidemiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


73. Pinkerton R, Wills RA, Coory MD, Fraser CJ: Survival from haematological malignancy in childhood, adolescence and young adulthood in Australia: is the age-related gap narrowing? Med J Aust; 2010 Aug 16;193(4):217-21
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN, SETTING AND PARTICIPANTS: Population-based study of all Australian children (aged 0-14 years), adolescents (15-19 years) and young adults (20-29 years) diagnosed with acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) between 1982 and 2004, with follow-up to 2006.
  • MAIN OUTCOME MEASURES: 5-year survival from ALL, AML, HL and NHL analysed for four periods of diagnosis (1982-1989, 1990-1994, 1995-1999 and 2000-2004).
  • RESULTS: During 1982-2004, 13 015 people aged < or = 29 years were diagnosed with primary leukaemia or lymphoma in Australia.
  • [MeSH-major] Leukemia / mortality. Lymphoma / mortality

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20712542.001).
  • [ISSN] 0025-729X
  • [Journal-full-title] The Medical journal of Australia
  • [ISO-abbreviation] Med. J. Aust.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


74. Nozaki H, Yanagida M, Koide K, Shiotani K, Kinoshita M, Kobayashi Y, Watarai S, Nakamura K, Suzuki A, Ariga T, Kushi Y: Production and characterization of monoclonal antibodies specific to lactotriaosylceramide. Glycobiology; 2010 Dec;20(12):1631-42
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have established hybridoma cell lines producing monoclonal antibodies (mAbs) directed to N-acetylglucosaminylβ1-3galactose (GlcNAcβ1-3Gal) residue by immunizing BALB/c mice with lactotriaosylceramide (Lc(3)Cer).
  • Furthermore, we have analyzed the expression of GSLs with GlcNAcβ1-3 epitope in acute leukemia cell lines and mouse fetal tissues using these mAbs, in which antigens were distributed comparatively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693232.001).
  • [ISSN] 1460-2423
  • [Journal-full-title] Glycobiology
  • [ISO-abbreviation] Glycobiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Immunoglobulin G; 0 / Immunoglobulin M; 0 / Immunoglobulin Variable Region; 0 / Lactosylceramides; 73467-80-8 / lactotriaosylceramide
  •  go-up   go-down


75. Dincaslan HU, Yavuz G, Unal E, Tacyildiz N, Ikinciogullari A, Dogu F, Guloglu D, Yuksek N, Ertem U: Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients? Pediatr Hematol Oncol; 2010 Oct;27(7):503-16
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does serum soluble vascular endothelial growth factor levels have different importance in pediatric acute leukemia and malignant lymphoma patients?
  • The aim of the study was to evaluate soluble VEGF (sVEGF) levels in children with acute leukemia and malignant lymphoma (ML) at diagnosis and in remission.
  • The levels of serum sVEGF were measured by enzyme-linked immunosorbent assay (ELISA) in 20 children with acute leukemia, 33 children with different histopathological subtypes of ML, and 20 healthy controls.
  • The levels of sVEGF at diagnosis (range 2 -1040 pg/mL; median 52 pg/mL) was significantly lower than in remission (range 136 -1960 pg/mL; median 630 pg/mL) in acute myeloid leukemia (AML) group (P = .018).
  • The sVEGF levels at diagnosis (range: 2 -640 pg/mL; median 89 pg/mL) was significantly lower compared to remission values (range: 116 -1960 pg/mL; median 136 pg/mL) in patients with acute lymphoblastic leukemia (ALL) (P = .002).
  • In ML group, including Burkitt's lymphoma (BL), T-cell non-Hodgkin's lymphoma (NHL), and Hodgkin's lymphoma (HL), sVEGF levels at diagnosis were higher than remission levels, but there was no statistically significant difference (P >.05).
  • On the other hand, there were significant difference between levels in active disease and control group, ie, BL versus control, T-cell NHL versus control, and HL versus control (P = .008, P = .043, P = .007, respectively).
  • The authors noticed that sVEGF levels showed distinct behavioral pattern in different childhood malignancies at diagnosis and in remission.
  • In acute leukemia and ML patients, VEGF acts through different pathophysiological mechanisms, in both bone marrow (BM) angiogenesis and lymphoid tissue lymphangiogenesis.
  • [MeSH-major] Hodgkin Disease / blood. Leukemia, Myeloid, Acute / blood. Lymphoma, Non-Hodgkin / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Vascular Endothelial Growth Factors / blood

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677920.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factors
  •  go-up   go-down


76. Radhi M, Meshinchi S, Gamis A: Prognostic factors in pediatric acute myeloid leukemia. Curr Hematol Malig Rep; 2010 Oct;5(4):200-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in pediatric acute myeloid leukemia.
  • Acute myeloid leukemia (AML), a heterogeneous group of diseases with variable responses to the same therapy, comprises nearly a quarter of childhood acute leukemias.
  • Although historically very few prognostic markers have been incorporated into therapeutic decision making in AML, recent advances in technology have enabled identification of numerous factors associated with disease outcome.
  • This review provides a detailed analysis of most clinically relevant factors associated with disease outcome in childhood AML.
  • [MeSH-major] Leukemia, Myeloid, Acute / diagnosis

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20652454.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


77. Duval M, Klein JP, He W, Cahn JY, Cairo M, Camitta BM, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D: Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol; 2010 Aug 10;28(23):3730-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.
  • PURPOSE: Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT).
  • PATIENTS AND METHODS: Overall, 2,255 patients who underwent transplantation for acute leukemia in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research.
  • RESULTS: The 3-year overall survival (OS) rates were 19% for acute myeloid leukemia (AML) and 16% for acute lymphoblastic leukemia (ALL).
  • HSCT during relapse can achieve long-term survival in selected patients with acute leukemia.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(9):1856-66 [10784626.001]
  • [Cites] Haematologica. 2010 Jun;95(6):989-95 [19951968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4075-83 [11110676.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1157-63 [11149725.001]
  • [Cites] Blood. 2003 Dec 15;102(13):4290-7 [12920027.001]
  • [Cites] Bone Marrow Transplant. 2004 Nov;34(9):799-806 [15361903.001]
  • [Cites] Am J Med. 1980 Aug;69(2):204-17 [6996481.001]
  • [Cites] Blood. 1992 Aug 15;80(4):1090-3 [1498326.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1391-5 [7858269.001]
  • [Cites] Bone Marrow Transplant. 1995 Jun;15(6):825-8 [7581076.001]
  • [Cites] Leuk Lymphoma. 1996 Jul;22(3-4):271-7 [8819076.001]
  • [Cites] Blood. 1997 Jun 1;89(11):4226-35 [9166868.001]
  • [Cites] Bone Marrow Transplant. 1998 Apr;21(7):673-8 [9578306.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3662-71 [10339472.001]
  • [Cites] Biol Blood Marrow Transplant. 2005 Feb;11(2):108-14 [15682071.001]
  • [Cites] Bone Marrow Transplant. 2005 Jul;36(2):157-62 [15937511.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):45-50 [16258531.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1092-9 [16551971.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Oct;12(10):1047-55 [17067911.001]
  • [Cites] Biom J. 2006 Dec;48(6):1029-40 [17240660.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] Stat Med. 2007 Oct 30;26(24):4505-19 [17348080.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jul;14(7):748-58 [18541193.001]
  • [Cites] Blood. 2008 Jul 15;112(2):415-25 [18451310.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25(9):943-8 [10800061.001]
  • (PMID = 20625136.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / U24 CA076518
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2917308
  •  go-up   go-down


78. Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S: Risks and outcome of fungal infection in neutropenic children with hematologic diseases. Turk J Pediatr; 2010 Mar-Apr;52(2):121-5
Hazardous Substances Data Bank. FLUCONAZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this retrospective study, we report the results of antifungal treatments (AFTs) in febrile neutropenic episodes in patients with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and aplastic anemia (AA) in our center.
  • [MeSH-major] Anemia, Aplastic / complications. Antifungal Agents / therapeutic use. Leukemia, Myeloid, Acute / complications. Mycoses / drug therapy. Neutropenia / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Aplastic Anemia.
  • MedlinePlus Health Information. consumer health - Fungal Infections.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20560245.001).
  • [ISSN] 0041-4301
  • [Journal-full-title] The Turkish journal of pediatrics
  • [ISO-abbreviation] Turk. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Antifungal Agents; 7XU7A7DROE / Amphotericin B; 8VZV102JFY / Fluconazole
  •  go-up   go-down


79. Sairafi D, Remberger M, Uhlin M, Ljungman P, Ringdén O, Mattsson J: Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions. Biol Blood Marrow Transplant; 2010 Dec;16(12):1728-37
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
  • A retrospective analysis was performed of 118 patients with hematologic malignancies who received donor lymphocyte infusions (DLIs) after allogeneic stem cell transplantation (ASCT).
  • Molecular relapse was in most cases based on leukemia lineage-specific chimerism analysis.
  • Patients with acute leukemia and myelodysplastic syndrome showed a 3-year survival of 42% if DLI treatment was given because of molecular relapse, compared to 16% in hematologic relapse (P < .006).
  • In multivariate analysis, there was a correlation between response to DLI and nonhematologic relapse (risk ratio [RR] 3.36, P = .001), chronic graft-versus-host disease (cGVHD) (RR = 1.51, P = .005), and late relapse (RR = 2.06, P = .017).
  • The overall incidences of acute GVHD (aGVHD) grades I-II and grades III-IV aGVHD were 33% and 8.5%, respectively.
  • To conclude, monitoring of leukemia lineage-specific chimerism is of utmost importance for DLI response after ASCT.
  • [MeSH-major] Hematologic Neoplasms / pathology. Hematologic Neoplasms / therapy. Leukemia / pathology. Leukemia / therapy. Lymphocyte Transfusion
  • [MeSH-minor] Adolescent. Adult. Cell Lineage. Child. Child, Preschool. Disease-Free Survival. Female. Graft vs Host Disease / diagnosis. Graft vs Host Disease / therapy. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged. Recurrence. Retrospective Studies. Tissue Donors. Transplantation Chimera. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20542125.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Keefe JG, Sukov WR, Knudson RA, Nguyen LP, Williamson C, Sinnwell JP, Ketterling RP: Development of five dual-color, double-fusion fluorescence in situ hybridization assays for the detection of common MLL translocation partners. J Mol Diagn; 2010 Jul;12(4):441-52
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chromosomal rearrangements involving the mixed lineage leukemia (MLL) gene at 11q23 are frequent in adult and childhood acute leukemia and have been associated with an unfavorable prognosis.
  • A blinded study was performed for each probe set using 25 normal bone marrow samples, 25 t(4;11), 20 t(6;11), 20 t(9;11), 18 t(11;19p13.1), and 20 t(11;19p13.3) leukemia specimens as defined by chromosome analysis.
  • A normal cutoff of 0.6% was established, suggesting an application for these assays in minimal residual disease detection and disease monitoring.
  • [MeSH-major] Biological Assay / methods. In Situ Hybridization, Fluorescence / methods. Myeloid-Lymphoid Leukemia Protein / genetics. Translocation, Genetic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Dec 1;90(11):4532-8 [9373264.001]
  • [Cites] Leukemia. 1996 Aug;10(8):1283-7 [8709632.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Leukemia. 1999 May;13(5):679-86 [10374870.001]
  • [Cites] Leukemia. 2006 Feb;20(2):218-23 [16341046.001]
  • [Cites] Leukemia. 2006 Apr;20(4):620-6 [16437134.001]
  • [Cites] Leukemia. 2006 May;20(5):777-84 [16511515.001]
  • [Cites] Cancer Genet Cytogenet. 2007 May;175(1):8-18 [17498552.001]
  • [Cites] J Clin Oncol. 2009 Jun 20;27(18):3000-6 [19380453.001]
  • [Cites] Haematologica. 2009 Jul;94(7):984-93 [19535349.001]
  • [Cites] Leukemia. 2009 Aug;23(8):1490-9 [19262598.001]
  • [Cites] Blood. 2009 Sep 17;114(12):2489-96 [19528532.001]
  • [Cites] Br J Haematol. 2000 Apr;109(1):13-23 [10848777.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2900-7 [11420702.001]
  • [Cites] Blood. 2001 Sep 15;98(6):1714-20 [11535502.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5695-707 [11607819.001]
  • [Cites] Nat Genet. 2002 Jan;30(1):41-7 [11731795.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2302-9 [11981001.001]
  • [Cites] Lancet. 2002 Jun 1;359(9321):1909-15 [12057554.001]
  • [Cites] Blood. 2002 Dec 15;100(13):4325-36 [12393746.001]
  • [Cites] Leukemia. 2003 Apr;17(4):700-6 [12682627.001]
  • [Cites] Br J Haematol. 2003 May;121(4):566-77 [12752097.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Sep;145(2):144-51 [12935927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2395-402 [12805060.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3093-6 [12842979.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Cancer Genet Cytogenet. 1988 May;32(1):59-66 [3281746.001]
  • [Cites] Cell. 1992 Nov 13;71(4):701-8 [1423625.001]
  • [Cites] Blood. 1993 May 1;81(9):2386-93 [8481519.001]
  • [Cites] Blood. 1993 Dec 15;82(12):3705-11 [8260707.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):909-15 [8164041.001]
  • [Cites] Blood. 1995 Jun 1;85(11):3250-6 [7756657.001]
  • [Cites] Blood. 1996 Apr 1;87(7):2870-7 [8639906.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):966-72 [8703835.001]
  • [Cites] Leukemia. 1998 May;12(5):840-4 [9593290.001]
  • (PMID = 20539022.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes; 0 / Nuclear Proteins; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein
  • [Other-IDs] NLM/ PMC2893628
  •  go-up   go-down


81. Cong W, Liu Q, Chen X, Gao R, Lu J, Wang Y, Luo G: Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm; 2010 Oct;36(10):1186-94
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and pharmacokinetics of a novel pirarubicin liposome powder.
  • BACKGROUND: Pirarubicin (THP), an analogue of doxorubicin, has exhibited promising activities against acute leukemia, malignant lymphoma, and several solid tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515395.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Excipients; 0 / Liposomes; 0 / Powders; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


82. Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W: Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia. Health Technol Assess; 2010 May;14 Suppl 1:69-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
  • This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of azacitidine (aza) compared with conventional care regimes (CCR) for higher risk patients with myelodysplastic syndrome (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML), based on the evidence submission from the manufacturer to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal process.
  • The results showed that: the median overall survival was 24.5 months on aza, compared with 15.0 months in the CCR group (p = 0.0001); the response rates were low (complete remission 17% aza versus 8% CCR); the median time to transformation to AML was greater in the aza group (17.8 versus 11.5 months; p < 0.0001); and of patients who were red blood cell (RBC) transfusion-dependent at baseline, 45% of those on aza became RBC transfusion-independent during the treatment period, compared with 11.8% in the CCR group (p < 0.0001).
  • At the time of writing, the guidance appraisal consultation document issued by NICE on 4 March 2010 states that azacitidine is not recommended as a treatment option for people not eligible for haemopoietic stem cell transplantation with the the following conditions: intermediate-2 and high-risk MDS according to the International Prognostic Scoring System, CMML with 10-29% marrow blasts without myeloproliferative disorder, or with AML with 20-30% blasts and multilineage dysplasia, according to World Health Organization classification.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Azacitidine / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myelomonocytic, Chronic / drug therapy. Myelodysplastic Syndromes / drug therapy


83. Naunheim MR, Nahed BV, Walcott BP, Kahle KT, Soupir CP, Cahill DP, Borges LF: Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature. Clin Neurol Neurosurg; 2010 Sep;112(7):575-7
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of acute lymphoblastic leukemia from intracerebral hemorrhage and blast crisis. A case report and review of the literature.
  • Intracerebral hemorrhage (ICH) contributes significantly to the morbidity and mortality of patients suffering from acute leukemia.
  • While ICH is often identified in autopsy studies of leukemic patients, it is rare for ICH to be the presenting sign that ultimately leads to the diagnosis of leukemia.
  • We report a patient with previously undiagnosed acute precursor B-cell lymphoblastic leukemia (ALL) who presented with diffuse encephalopathy due to ICH in the setting of an acute blast crisis.
  • The diagnosis of ALL was initially suspected, because of the hyperleukocytosis observed on presentation, then confirmed with a bone marrow biopsy and flow cytometry study of the peripheral blood.
  • Furthermore, detection of the BCR/ABL Philadelphia translocation t(9:22)(q34:q11) in this leukemic patient by fluorescent in situ hybridization permitted targeted therapy of the blast crisis with imatinib (Gleevec).
  • This case demonstrates that the presence of hyperleukocytosis in a patient with intracerebral hemorrhage should raise clinical suspicion for acute leukemia as the cause of the ICH.
  • [MeSH-major] Blast Crisis / diagnosis. Intracranial Hemorrhages / diagnosis. Leukemia, Biphenotypic, Acute / diagnosis
  • [MeSH-minor] Benzamides. Blood Cell Count. Diagnosis, Differential. Flow Cytometry. Humans. Imatinib Mesylate. In Situ Hybridization. Leukocyte Count. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20493628.001).
  • [ISSN] 1872-6968
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


84. Wun T, White RH: Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. Thromb Res; 2010 Apr;125 Suppl 2:S96-102
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma.
  • A growing number of studies have demonstrated that the risk of VTE associated with the hematological malignancies acute leukemia, lymphoma, and multiple myeloma is considerable.
  • [MeSH-major] Leukemia / complications. Lymphoma / complications. Multiple Myeloma / complications. Venous Thromboembolism / epidemiology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20434017.001).
  • [ISSN] 1879-2472
  • [Journal-full-title] Thrombosis research
  • [ISO-abbreviation] Thromb. Res.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / UL1 RR024146
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants
  • [Number-of-references] 60
  •  go-up   go-down


85. Casado Picón R, Barrios López M, de Inocencio Arocena J, Baro Fernández M, Vivanco Martínez JL: [Musculoskeletal pain: a common initial sign of acute lymphoblastic leukaemia]. An Pediatr (Barc); 2010 Jun;72(6):428-31
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal pain: a common initial sign of acute lymphoblastic leukaemia].
  • [Transliterated title] Dolor musculoesquelético: una forma de inicio frecuente de leucemia linfoblástica aguda.
  • Nevertheless neoplasms, particularly acute leukaemia, must be considered in the differential diagnosis.
  • During the last 9 months 4 of the 9 patients diagnosed with acute leukaemia at our hospital presented with a limp, arthralgias, lumbar or bony pain.
  • We describe these cases and review the clinical and analytical parameters that help to differentiate benign pain from that associated with a malignant disease.
  • [MeSH-major] Musculoskeletal System. Pain / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Asociación Española de Pediatría. Published by Elsevier Espana. All rights reserved.
  • (PMID = 20417164.001).
  • [ISSN] 1695-9531
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


86. Haferlach T, Kohlmann A, Wieczorek L, Basso G, Kronnie GT, Béné MC, De Vos J, Hernández JM, Hofmann WK, Mills KI, Gilkes A, Chiaretti S, Shurtleff SA, Kipps TJ, Rassenti LZ, Yeoh AE, Papenhausen PR, Liu WM, Williams PM, Foà R: Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol; 2010 May 20;28(15):2529-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group.
  • PURPOSE: The Microarray Innovations in Leukemia study assessed the clinical utility of gene expression profiling as a single test to subtype leukemias into conventional categories of myeloid and lymphoid malignancies.
  • An exploratory retrospective stage I study was designed for biomarker discovery and generated whole-genome expression profiles from 2,143 patients with leukemias and myelodysplastic syndromes.
  • In a second cohort of 1,152 prospectively collected patients, a classification scheme reached 95.6% median sensitivity and 99.8% median specificity for 14 standard subtypes of acute leukemia (eight acute lymphoblastic leukemia and six acute myeloid leukemia classes, n = 693).
  • CONCLUSION: Gene expression profiling is a robust technology for the diagnosis of hematologic malignancies with high accuracy.
  • Our comprehensive gene expression data set will be submitted to the public domain to foster research focusing on the molecular understanding of leukemias.
  • [MeSH-major] Leukemia / classification. Leukemia / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Rev Clin Oncol. 2010 Aug;7(8):422 [20700897.001]
  • (PMID = 20406941.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA081534
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


87. Hwang YY, Liang R: Antifungal prophylaxis and treatment in patients with hematological malignancies. Expert Rev Anti Infect Ther; 2010 Apr;8(4):397-404
MedlinePlus Health Information. consumer health - Fungal Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20377335.001).
  • [ISSN] 1744-8336
  • [Journal-full-title] Expert review of anti-infective therapy
  • [ISO-abbreviation] Expert Rev Anti Infect Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 48
  •  go-up   go-down


88. Gra O, Mityaeva O, Berdichevets I, Kozhekbaeva Z, Fesenko D, Kurbatova O, Goldenkova-Pavlova I, Nasedkina T: Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1, and AB0 allele frequencies in native Russians. Genet Test Mol Biomarkers; 2010 Jun;14(3):329-42
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These data were used in comparative studies to determine predisposition to tuberculosis, lymphoma, and leukemia in adults and to childhood acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20373852.001).
  • [ISSN] 1945-0257
  • [Journal-full-title] Genetic testing and molecular biomarkers
  • [ISO-abbreviation] Genet Test Mol Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / HLA-DQ Antigens; 0 / HLA-DQ alpha-Chains; 0 / HLA-DQA1 antigen; 0 / Xenobiotics; EC 1.- / Mixed Function Oxygenases; EC 1.- / Oxidoreductases; EC 1.14.13.- / CYP2C9 protein, human; EC 1.14.13.- / Cytochrome P-450 CYP2C19; EC 1.14.13.- / Cytochrome P-450 CYP2C9; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2C19 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1A1; EC 1.14.14.1 / Cytochrome P-450 CYP2D6; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 1.6.5.2 / NAD(P)H Dehydrogenase (Quinone); EC 1.6.5.2 / NQO1 protein, human; EC 2.3.1.5 / Arylamine N-Acetyltransferase; EC 2.3.1.5 / NAT2 protein, human; EC 2.5.1.- / glutathione S-transferase T1; EC 2.5.1.18 / Glutathione Transferase; EC 2.5.1.18 / glutathione S-transferase M1
  •  go-up   go-down


89. Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM: Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets; 2010 Jun;10(4):384-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CREB is a critical regulator of cell differentiation, proliferation and survival in the nervous system.
  • Overexpression and over-activation of CREB were observed in cancer tissues from patients with prostate cancer, breast cancer, non-small-cell lung cancer and acute leukemia while down-regulation of CREB in several distinct cancer cell lines resulted in inhibition of cell proliferation and induction of apoptosis, suggesting that CREB may be a promising target for cancer therapy.

  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cancer Res. 2009 May;7(5):654-64 [19435810.001]
  • [Cites] Am J Pathol. 2009 Nov;175(5):2197-206 [19815709.001]
  • [Cites] Chembiochem. 2009 Nov 23;10(17):2721-4 [19810079.001]
  • [Cites] J Clin Invest. 1991 Sep;88(3):1038-42 [1832173.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(5):1546-52 [10669732.001]
  • [Cites] Annu Rev Biochem. 1999;68:821-61 [10872467.001]
  • [Cites] J Biol Chem. 2000 Nov 10;275(45):35242-7 [10952992.001]
  • [Cites] Nature. 2001 May 17;411(6835):342-8 [11357141.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609 [11483993.001]
  • [Cites] Blood. 2002 Apr 1;99(7):2617-9 [11895805.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43168-74 [12205094.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15626-31 [12438686.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1338-46 [14973073.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3395-405 [15150091.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Apr;81(8):2534-7 [6326131.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Sep;83(18):6682-6 [2875459.001]
  • [Cites] Nature. 1987 Jul 9-15;328(6126):175-8 [2885756.001]
  • [Cites] Science. 1989 Nov 17;246(4932):911-6 [2683088.001]
  • [Cites] Oncogene. 1996 May 16;12(10):2223-33 [8668349.001]
  • [Cites] FEBS Lett. 1989 Dec 18;259(1):61-3 [2532156.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1503-12 [1532935.001]
  • [Cites] Mol Endocrinol. 1992 Apr;6(4):647-55 [1350057.001]
  • [Cites] Nature. 1992 Sep 10;359(6391):162-5 [1522903.001]
  • [Cites] Nat Genet. 1993 Aug;4(4):341-5 [8401579.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5330-4 [8202489.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5647-51 [8202542.001]
  • [Cites] Cell. 1994 Jun 3;77(5):713-25 [8205620.001]
  • [Cites] Oncogene. 1996 Jan 4;12(1):159-67 [8552387.001]
  • [Cites] Genes Dev. 1989 Dec;3(12B):2083-90 [2516827.001]
  • [Cites] Science. 1996 Aug 16;273(5277):959-63 [8688081.001]
  • [Cites] EMBO J. 1996 Sep 2;15(17):4629-42 [8887554.001]
  • [Cites] Oncogene. 1997 May 1;14(17):2071-8 [9160887.001]
  • [Cites] Curr Opin Struct Biol. 1997 Jun;7(3):355-61 [9204277.001]
  • [Cites] Nature. 1997 Sep 18;389(6648):239-42 [9305836.001]
  • [Cites] Oncogene. 1997 Oct 23;15(17):2069-75 [9366524.001]
  • [Cites] Cell. 1997 Dec 12;91(6):741-52 [9413984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4481-6 [9539763.001]
  • [Cites] J Biol Chem. 1998 Dec 4;273(49):32377-9 [9829964.001]
  • [Cites] J Biol Chem. 1999 Jan 15;274(3):1573-80 [9880535.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Nov 30;101(48):16768-73 [15556999.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17622-7 [15585582.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):351-62 [15837624.001]
  • [Cites] Anal Biochem. 2005 May 15;340(2):259-71 [15840499.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1044:109-16 [15958703.001]
  • [Cites] Trends Cell Biol. 2005 Sep;15(9):457-9 [16084096.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1134-5 [16096372.001]
  • [Cites] Oncogene. 2005 Nov 10;24(49):7310-9 [16158061.001]
  • [Cites] J Mol Biol. 2006 Feb 3;355(5):1005-13 [16253272.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1547-52 [16671086.001]
  • [Cites] Front Biosci. 2007;12:1814-32 [17127423.001]
  • [Cites] Cancer. 2007 Mar 15;109(6):1164-73 [17315157.001]
  • [Cites] Angew Chem Int Ed Engl. 2007;46(16):2865-8 [17351994.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3663-72 [17440078.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2784-94 [17473212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10418-23 [17566103.001]
  • [Cites] J Comb Chem. 2007 Jul-Aug;9(4):592-600 [17530904.001]
  • [Cites] Oncogene. 2007 Aug 2;26(35):5070-7 [17310988.001]
  • [Cites] Oncol Rep. 2007 Oct;18(4):953-8 [17786359.001]
  • [Cites] Endocr Relat Cancer. 2007 Sep;14(3):531-47 [17914087.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1435-7 [18024382.001]
  • [Cites] Nature. 2007 Dec 13;450(7172):1001-9 [18075579.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1182-92 [17975014.001]
  • [Cites] Cancer Res. 2008 Feb 15;68(4):981-8 [18281471.001]
  • [Cites] Leukemia. 2008 Mar;22(3):665-7 [17805329.001]
  • [Cites] Apoptosis. 2008 May;13(5):681-92 [18392938.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6065-73 [18676828.001]
  • [Cites] Nat Chem Biol. 2008 Nov;4(11):648-9 [18936744.001]
  • [Cites] Cancer Res. 2008 Dec 1;68(23):9663-70 [19047143.001]
  • [Cites] Ann N Y Acad Sci. 2009 Feb;1155:121-31 [19250199.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2471-8 [19258499.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2583-7 [19351775.001]
  • [Cites] ACS Chem Biol. 2009 May 15;4(5):335-44 [19348463.001]
  • (PMID = 20370681.001).
  • [ISSN] 1873-5576
  • [Journal-full-title] Current cancer drug targets
  • [ISO-abbreviation] Curr Cancer Drug Targets
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL075826; United States / NIGMS NIH HHS / GM / R01 GM087305; United States / NHLBI NIH HHS / HL / HL83077; United States / NHLBI NIH HHS / HL / HL75826; United States / NHLBI NIH HHS / HL / R01 HL083077; United States / NICHD NIH HHS / HD / K12 HD034610; United States / NICHD NIH HHS / HD / HD034610-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cyclic AMP Response Element-Binding Protein
  • [Other-IDs] NLM/ NIHMS635161; NLM/ PMC4206256
  •  go-up   go-down


90. Wongprajun S, Auewarakul CU: A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy. J Med Assoc Thai; 2010 Jan;93 Suppl 1:S157-64
MedlinePlus Health Information. consumer health - Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A method comparison study of flow cytometry and cytomorphology to determine the percentages of blasts in patients with acute leukemia after induction and consolidation chemotherapy.
  • BACKGROUND: Enumeration of blasts in the bone marrow is an essential component in the diagnosis and treatment of acute leukemia.
  • The current gold standard method is based on a morphologic counting of 500 marrow nucleated cells despite its operator dependence and inter-observer variability.
  • OBJECTIVES: To compare the percentages of marrow blasts derived from two different approaches comprising routine morphology-based manual counting and flow cytometric analysis.
  • MATERIAL AND METHOD: Fifty-five marrow samples were collected from 38 acute leukemia patients (36 AML and 19 ALL) after hematologic recovery from chemotherapy.
  • The blast percentages were enumerated manually and by flow cytometer using CD45 and side scatter gates.
  • The blast percentages derived from flow cytometer were higher than from morphologic counting in 46 samples (83.6%).
  • [MeSH-major] Bone Marrow Cells / cytology. Cell Count / methods. Flow Cytometry / methods. Leukemia / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20364570.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


91. Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, Introna M, Pesenti E, Ciomei M, Golay J: Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models. Exp Hematol; 2010 Apr;38(4):259-269.e2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
  • MATERIALS AND METHODS: Thirteen leukemic cell lines bearing different cytogenetic abnormalities and normal hematopoietic cells were used in cytotoxicity and colony assays.
  • PHA-793887 was also tested in vivo in several leukemia xenograft models.
  • RESULTS: PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 microM (mean: 2.9 microM), regardless of any specific chromosomal aberration.
  • Interestingly, in colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 microM (mean: 0.08 microM), indicating that it has efficient and prolonged antiproliferative activity.
  • PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation, and modulated cyclin E and cdc6 expression at low doses (0.2-1 microM) and induced apoptosis at the highest dose (5 microM).
  • It was also effective in vivo in both subcutaneous xenograft and primary leukemic disseminated models that better mimic naturally occurring human disease.
  • Interestingly, in one disseminated model derived from a relapsed Philadelphia-positive acute lymphoid leukemia patient, PHA-793887 showed strong therapeutic activity also when treatment was started after establishment of high disease burden.
  • CONCLUSIONS: We conclude that PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cyclin-Dependent Kinases / antagonists & inhibitors. Leukemia / drug therapy
  • [MeSH-minor] Animals. Apoptosis. Blotting, Western. Cell Cycle / drug effects. Cell Line, Tumor. Disease Models, Animal. Drug Screening Assays, Antitumor. Humans. Immunohistochemistry. Inhibitory Concentration 50. Mice. Mice, SCID

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20167248.001).
  • [ISSN] 1873-2399
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


92. Kletting P, Kull T, Bunjes D, Mahren B, Luster M, Reske SN, Glatting G: Radioimmunotherapy with anti-CD66 antibody: improving the biodistribution using a physiologically based pharmacokinetic model. J Nucl Med; 2010 Mar;51(3):484-91
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The biodistribution of the (111)In-labeled anti-CD66 antibody of 8 patients with acute leukemia was measured.
  • [MeSH-major] Antibodies / immunology. Antibodies / therapeutic use. Antigens, CD / immunology. Cell Adhesion Molecules / immunology. Models, Biological. Radioimmunotherapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Leukemia / metabolism. Leukemia / physiopathology. Leukemia / radiotherapy. Male. Middle Aged. Reproducibility of Results. Tissue Distribution. Yttrium Radioisotopes / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20150257.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens, CD; 0 / CD66 antigens; 0 / Cell Adhesion Molecules; 0 / Yttrium Radioisotopes
  •  go-up   go-down


93. Liseth K, Sjo M, Paulsen K, Bruserud Ø, Ersvaer E: Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease. Eur Cytokine Netw; 2010 Mar;21(1):40-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early pre-engraftment, functional, in vitro responsiveness of T lymphocytes in allotransplanted, acute leukemia patients: proliferation and release of a broad profile of cytokines, possibly predictive of graft-versus-host disease.
  • Previous studies of T cell reconstitution following allogeneic stem cell transplantation have described long-lasting T cell defects, including decreased levels of autocrine proliferating CD4+ T cells.
  • However, T cell functions during the early phase of conditioning-induced, pre-engraftment pancytopenia have not been characterized previously.
  • We used a whole blood assay to investigate T cell proliferation and cytokine release during the period of pre-engraftment cytopenia.
  • The study included 13 acute leukemia patients receiving myeloablative conditioning followed by transplantation of G-CSF-mobilised peripheral blood stem cells derived from HLA-matched family donors.
  • The capacity of circulating T cells derived during pre-engraftment cytopenia to release high levels of IFNgamma, IL-6 and IL-17 in response to in vitro activation with anti-CD3+anti-CD28 showed statistically significant correlations with later acute GVHD.
  • We conclude that allotransplanted patients have a functional T cell system even during the pre-engraftment period of severe pancytopenia.
  • [MeSH-major] Cytokines / secretion. Graft vs Host Disease / diagnosis. Graft vs Host Disease / immunology. Peripheral Blood Stem Cell Transplantation. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. T-Lymphocytes / immunology
  • [MeSH-minor] Adolescent. Adult. Cell Proliferation. Female. Humans. Interferon-gamma / immunology. Lymphocyte Activation / immunology. Lymphocyte Count. Male. Middle Aged. Prognosis. Signal Transduction / immunology. Transplantation Conditioning. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20146989.001).
  • [ISSN] 1952-4005
  • [Journal-full-title] European cytokine network
  • [ISO-abbreviation] Eur. Cytokine Netw.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Cytokines; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


94. Sewak MS, Reddy NP, Duan ZH: Gene expression based leukemia sub-classification using committee neural networks. Bioinform Biol Insights; 2009 Sep 03;3:89-98

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression based leukemia sub-classification using committee neural networks.
  • Analysis of gene expression data provides an objective and efficient technique for sub-classification of leukemia.
  • The purpose of the present study was to design a committee neural networks based classification systems to subcategorize leukemia gene expression data.
  • In the study, a binary classification system was considered to differentiate acute lymphoblastic leukemia from acute myeloid leukemia.
  • A ternary classification system which classifies leukemia expression data into three subclasses including B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia and acute myeloid leukemia was also developed.
  • In each classification system gene expression profiles of leukemia patients were first subjected to a sequence of simple preprocessing steps.
  • This resulted in filtering out approximately 95 percent of the non-informative genes.
  • The binary classification system classified microarray gene expression profiles into two categories with 100 percent accuracy and the ternary system correctly predicted the three subclasses of leukemia in over 97 percent of the cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] Pac Symp Biocomput. 2003;:5-16 [12603013.001]
  • [Cites] Bioinformatics. 2003 Jun 12;19(9):1132-9 [12801874.001]
  • [Cites] FEBS Lett. 2003 Dec 4;555(2):358-62 [14644442.001]
  • [Cites] Bioinformatics. 2005 Mar 1;21(5):631-43 [15374862.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1189-98 [15878973.001]
  • [Cites] BMC Med Inform Decis Mak. 2006;6:27 [16790051.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):644-52 [15033871.001]
  • [Cites] BMC Bioinformatics. 2004 Sep 27;5:136 [15450124.001]
  • (PMID = 20140065.001).
  • [ISSN] 1177-9322
  • [Journal-full-title] Bioinformatics and biology insights
  • [ISO-abbreviation] Bioinform Biol Insights
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2808175
  • [Keywords] NOTNLM ; gene selection / leukemia cancer / microarray / neural networks / sample classification
  •  go-up   go-down


95. Kim HP, Frankel AE, Hogge DE: A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leuk Res; 2010 Aug;34(8):1035-42
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia.
  • Despite initial remissions, most patients with Ph chromosome positive (Ph(+)) acute leukemia (AL) become refractory to tyrosine kinase inhibitors (TKIs) such as imatinib and dasatinib.
  • IL-3R subunits were detected on most Ph(+) cells and the IC50 for killing of colony forming cell (CFC) with DT(388)IL3 correlated with the level of IL-3Ralpha subunit by FACS.
  • Long-term suspension culture-initiating cells (SC-ICs) and quiescent leukemic cells (G(0) in cell cycle) also were studied and synergistic interactions were again demonstrated.
  • [MeSH-major] Diphtheria Toxin / therapeutic use. Fusion Proteins, bcr-abl / genetics. Interleukin-3 / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Neoplastic Stem Cells / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors. Recombinant Fusion Proteins / therapeutic use
  • [MeSH-minor] Adult. Aged. Benzamides. Blotting, Western. Cell Cycle. Cell Proliferation. Cells, Cultured. Dasatinib. Drug Synergism. Female. Flow Cytometry. Humans. Imatinib Mesylate. Interleukin-3 Receptor alpha Subunit / genetics. Interleukin-3 Receptor alpha Subunit / metabolism. Male. Middle Aged. Piperazines / therapeutic use. Pyrimidines / therapeutic use. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Thiazoles / therapeutic use

  • Genetic Alliance. consumer health - Diphtheria.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20137810.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Diphtheria Toxin; 0 / IL3RA protein, human; 0 / Interleukin-3; 0 / Interleukin-3 Receptor alpha Subunit; 0 / Piperazines; 0 / Pyrimidines; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 0 / Thiazoles; 0 / diphtheria toxin-interleukin-3 fusion protein, recombinant; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Fusion Proteins, bcr-abl; RBZ1571X5H / Dasatinib
  •  go-up   go-down


96. Zhou GN, Chen BA: [M-FISH technique in diagnosis and prognostic analysis for acute leukemia with complex chromosomal aberrations]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb;18(1):246-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [M-FISH technique in diagnosis and prognostic analysis for acute leukemia with complex chromosomal aberrations].
  • In leukaemia cytogenetics, the M-FISH now is used in detection for AL patients with following chromosome abnormality:.
  • (2) chromosome translocation with complex abnormal karyotypes exists in patients with leukemia which are difficulty detected by using conventional method.
  • The final results detected by M-FISH have guide significance for diagnosis, therapy and prognosis of AL patients.
  • In this article the technical basis with commonly used probe for M-FISH, application of M-FISH in diagnosis, evaluation of therapeutic efficacy and prognostic analysis of AL patients are summarised.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137157.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


97. Huang HW, Wu DP: [Advances of study on PPARgamma/PPARgamma ligand in hematologic malignancies]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec;17(6):1592-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This review focuses the advances of study on PPARgamma distribution in tissue, its function, its ligand in relationship with hematologic malignancies including acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, lymphoma, multiple myeloma and so on.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20030954.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ligands; 0 / PPAR gamma
  •  go-up   go-down


98. Apelseth TO, Bruserud O, Wentzel-Larsen T, Hervig T: Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods. Transfusion; 2010 Apr;50(4):766-75
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods.
  • In this study we evaluate and compare transfusion effect measures in patients with chemotherapy-induced thrombocytopenia due to treatment of acute leukemia.
  • Patient and PC variables influencing the effect of transfusion were analyzed by use of a mixed-effects model.
  • RESULTS: PLT dose, storage time, and pathogen inactivation correlated with PLT recovery but not with PLT survival (including ITI), TEG, or clinical bleeding.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Platelet Transfusion / methods. Thrombocytopenia / chemically induced. Thrombocytopenia / therapy
  • [MeSH-minor] ABO Blood-Group System. Blood Platelets / cytology. Blood Platelets / physiology. Body Surface Area. Carbon Dioxide / blood. Cell Survival. Documentation. Female. Hemorrhage / blood. Hemorrhage / chemically induced. Hospitals, University. Humans. Male. Norway. Oxygen / blood. Platelet Count. Prospective Studies

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. Carbon dioxide .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transfusion. 2010 Nov;50(11):2504; author reply 2505-6 [21182633.001]
  • (PMID = 20030789.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System; 0 / Antineoplastic Agents; 142M471B3J / Carbon Dioxide; S88TT14065 / Oxygen
  •  go-up   go-down


99. Chen J, Odenike O, Rowley JD: Leukaemogenesis: more than mutant genes. Nat Rev Cancer; 2010 Jan;10(1):23-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Acute leukaemias are characterized by recurring chromosomal aberrations and gene mutations that are crucial to disease pathogenesis.
  • It is now evident that epigenetic modifications, including DNA methylation and histone modifications, substantially contribute to the phenotype of leukaemia cells.
  • An additional layer of epigenetic complexity is the pathogenetic role of microRNAs in leukaemias, and their key role in the transcriptional regulation of tumour suppressor genes and oncogenes.
  • The genetic heterogeneity of acute leukaemias poses therapeutic challenges, but pharmacological agents that target components of the epigenetic machinery are promising as a component of the therapeutic arsenal for this group of diseases.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Feb;17(2):350-8 [12592335.001]
  • [Cites] Cancer Cell. 2003 Mar;3(3):259-71 [12676584.001]
  • [Cites] N Engl J Med. 2003 Nov 20;349(21):2042-54 [14627790.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8955-61 [14695213.001]
  • [Cites] Nat Rev Cancer. 2004 Feb;4(2):143-53 [14732866.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7837-41 [6818551.001]
  • [Cites] Nature. 1983 Nov 17-23;306(5940):239-42 [6316147.001]
  • [Cites] Cell. 1984 Jan;36(1):93-9 [6319012.001]
  • [Cites] Blood. 1988 Aug;72(2):567-72 [3165295.001]
  • [Cites] Nature. 1990 Oct 11;347(6293):558-61 [2170850.001]
  • [Cites] Science. 1990 Sep 28;249(4976):1577-80 [2218500.001]
  • [Cites] J Exp Med. 1990 Dec 1;172(6):1571-5 [2175343.001]
  • [Cites] N Engl J Med. 1991 May 16;324(20):1385-93 [1850498.001]
  • [Cites] Cell. 1991 Aug 23;66(4):663-74 [1652368.001]
  • [Cites] Cell. 1991 Aug 23;66(4):675-84 [1652369.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10735-9 [1720549.001]
  • [Cites] Blood. 1992 Oct 1;80(7):1825-31 [1391946.001]
  • [Cites] EMBO J. 1993 Mar;12(3):1161-7 [8384553.001]
  • [Cites] N Engl J Med. 1993 Sep 23;329(13):909-14 [8361504.001]
  • [Cites] Blood. 1995 Feb 15;85(4):1083-94 [7849296.001]
  • [Cites] Blood. 1996 Feb 1;87(3):882-6 [8562957.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):33-41 [8782817.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8732-7 [9238046.001]
  • [Cites] Science. 1997 Nov 7;278(5340):1059-64 [9353180.001]
  • [Cites] Nat Genet. 1998 Feb;18(2):126-35 [9462740.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):811-4 [9486654.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):815-8 [9486655.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10860-5 [9724795.001]
  • [Cites] Blood. 1998 Sep 15;92(6):2118-22 [9731070.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5 [9811311.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7176-84 [9819404.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7185-91 [9819405.001]
  • [Cites] Nat Genet. 1999 Jan;21(1):103-7 [9916800.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2766-9 [10383127.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3730-40 [10446989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54 [15640349.001]
  • [Cites] Blood. 2005 Feb 1;105(3):959-67 [15466934.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1277-84 [15735013.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] J Cell Biochem. 2005 May 15;95(2):234-42 [15779005.001]
  • [Cites] Cell. 2005 Apr 22;121(2):167-78 [15851025.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7653-8 [15894607.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):828-33 [15944707.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):839-43 [15944709.001]
  • [Cites] Mol Cell Biol. 2005 Jul;25(14):5869-79 [15988004.001]
  • [Cites] Haematologica. 2005 Jul;90(7):986-8 [15996941.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6285-95 [16155011.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6306-15 [16155013.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13944-9 [16166262.001]
  • [Cites] Cell. 2005 Oct 21;123(2):207-18 [16239140.001]
  • [Cites] Cancer Res. 2005 Nov 1;65(21):9628-32 [16266980.001]
  • [Cites] J Cell Biochem. 2005 Dec 1;96(5):938-50 [16167339.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):112-9 [16323176.001]
  • [Cites] Leukemia. 2006 Feb;20(2):212-7 [16357841.001]
  • [Cites] Cancer Cell. 2006 Feb;9(2):73-4 [16473273.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):287-97 [11703323.001]
  • [Cites] EMBO J. 2001 Dec 17;20(24):7184-96 [11742995.001]
  • [Cites] Nat Rev Cancer. 2001 Dec;1(3):245-50 [11902580.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):963-70 [11948101.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2429-40 [12011120.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2441-52 [12011121.001]
  • [Cites] Nat Med. 2002 Jul;8(7):743-50 [12091906.001]
  • [Cites] Blood. 2002 Oct 15;100(8):2957-64 [12351408.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1107-17 [12453418.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1119-28 [12453419.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 26;99(24):15524-9 [12434020.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3895-903 [16921040.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8903-11 [16951208.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2707-16 [16981007.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8191-201 [16940181.001]
  • [Cites] Cancer. 2006 Oct 15;107(8):1839-43 [16967444.001]
  • [Cites] Nat Rev Cancer. 2006 Nov;6(11):857-66 [17060945.001]
  • [Cites] Leukemia. 2006 Nov;20(11):1931-6 [16990772.001]
  • [Cites] Cancer. 2006 Nov 1;107(9):2099-107 [17019734.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Mol Cancer Ther. 2006 Dec;5(12):3096-104 [17172412.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):91-101 [16799637.001]
  • [Cites] Hum Mol Genet. 2007 Jan 1;16(1):92-106 [17135274.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2135-43 [17135249.001]
  • [Cites] J Biol Chem. 2007 Jan 26;282(4):2130-4 [17135268.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):953-60 [17163415.001]
  • [Cites] Nat Rev Drug Discov. 2007 Feb;6(2):149-65 [17268486.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2750-5 [17293455.001]
  • [Cites] Science. 2007 Mar 16;315(5818):1576-9 [17322030.001]
  • [Cites] Ann Hematol. 2007 May;86(5):311-27 [17375301.001]
  • [Cites] Exp Hematol. 2007 Apr;35(4):551-64 [17379065.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Science. 2007 Apr 27;316(5824):604-8 [17463289.001]
  • [Cites] Science. 2007 Apr 27;316(5824):608-11 [17463290.001]
  • [Cites] Genes Dev. 2007 May 1;21(9):1050-63 [17437993.001]
  • [Cites] Blood. 2007 Apr 1;109(7):2781-90 [17179232.001]
  • [Cites] Cancer Cell. 2007 Jun;11(6):513-25 [17560333.001]
  • [Cites] Oncogene. 2007 Jun 14;26(28):4148-57 [17260024.001]
  • [Cites] Nat Cell Biol. 2007 Jul;9(7):775-87 [17589498.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3884-91 [17679729.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2302-8 [17596541.001]
  • [Cites] Braz J Med Biol Res. 2007 Nov;40(11):1435-40 [17934639.001]
  • [Cites] Nat Rev Cancer. 2007 Nov;7(11):823-33 [17957188.001]
  • [Cites] Oncologist. 2007 Oct;12(10):1247-52 [17962618.001]
  • [Cites] Exp Hematol. 2007 Nov;35(11):1657-67 [17976518.001]
  • [Cites] Nat Struct Mol Biol. 2007 Nov;14(11):1008-16 [17984963.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 21;364(3):509-14 [17964546.001]
  • [Cites] Cancer Cell. 2007 Nov;12(5):457-66 [17996649.001]
  • [Cites] Nat Rev Mol Cell Biol. 2007 Dec;8(12):983-94 [18037899.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4445-54 [17855633.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19971-6 [18056805.001]
  • [Cites] Immunity. 2007 Dec;27(6):847-59 [18055230.001]
  • [Cites] Mol Cell Biol. 2008 Jan;28(2):752-71 [17991895.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1060-6 [17962510.001]
  • [Cites] Int J Hematol. 2008 Jan;87(1):10-8 [18224408.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):826-32 [18245545.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Nat Struct Mol Biol. 2008 Mar;15(3):268-79 [18311151.001]
  • [Cites] Nat Struct Mol Biol. 2008 Mar;15(3):259-67 [18311153.001]
  • [Cites] Cell. 2008 Mar 7;132(5):860-74 [18329371.001]
  • [Cites] Cell. 2008 Mar 7;132(5):875-86 [18329372.001]
  • [Cites] Blood. 2008 Mar 15;111(6):3183-9 [18187662.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3945-50 [18308931.001]
  • [Cites] J Exp Med. 2008 Mar 17;205(3):585-94 [18299402.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1635-40 [14604977.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Science. 2004 Apr 23;304(5670):594-6 [15105502.001]
  • [Cites] Nat Rev Genet. 2004 Jul;5(7):522-31 [15211354.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11755-60 [15284443.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1266-9 [15155466.001]
  • [Cites] Ann Genet. 1973 Jun;16(2):109-12 [4125056.001]
  • [Cites] Blood. 1973 Sep;42(3):359-65 [4125239.001]
  • [Cites] Nature. 1973 Jun 1;243(5405):290-3 [4126434.001]
  • [Cites] Lancet. 1977 Mar 5;1(8010):549-50 [65649.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 [6961453.001]
  • [Cites] Nat Immunol. 2008 Apr;9(4):405-14 [18327259.001]
  • [Cites] Science. 2008 Apr 4;320(5872):97-100 [18292307.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1919-28 [18450603.001]
  • [Cites] Blood. 2008 May 15;111(10):5078-85 [18337557.001]
  • [Cites] Cancer Gene Ther. 2008 Jun;15(6):341-55 [18369380.001]
  • [Cites] Leukemia. 2008 May;22(5):915-31 [18288131.001]
  • [Cites] PLoS One. 2008;3(5):e2141 [18478077.001]
  • [Cites] Oncogene. 2008 Jun 5;27(25):3615-23 [18223691.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):352-8 [18536574.001]
  • [Cites] Leukemia. 2008 Jun;22(6):1095-105 [18323801.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):36-46 [18598942.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):40-8 [18407786.001]
  • [Cites] Blood. 2008 Aug 15;112(4):981-9 [18495956.001]
  • [Cites] Nature. 2008 Aug 7;454(7205):711-5 [18685699.001]
  • [Cites] J Cell Biol. 2008 Aug 11;182(3):509-17 [18695042.001]
  • [Cites] Blood. 2008 Sep 15;112(6):2183-9 [18779403.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 7;105(40):15535-40 [18832181.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5078-87 [18809607.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):355-68 [18977325.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):7095-101 [18981008.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9358-66 [19010910.001]
  • [Cites] Nat Med. 2008 Dec;14(12):1333-42 [19029980.001]
  • [Cites] Semin Hematol. 2009 Jan;46(1):24-32 [19100365.001]
  • [Cites] Blood. 2009 Jan 8;113(2):396-402 [18941111.001]
  • [Cites] Blood. 2009 Jan 8;113(2):412-21 [18941112.001]
  • [Cites] Blood. 2009 Jan 15;113(3):505-16 [18818396.001]
  • [Cites] Cancer Res. 2009 Feb 1;69(3):1109-16 [19155294.001]
  • [Cites] Leukemia. 2009 Feb;23(2):313-22 [18923441.001]
  • [Cites] J Immunol. 2009 Mar 1;182(5):2578-82 [19234151.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2735-40 [19193853.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2812-7 [19196975.001]
  • [Cites] J Clin Oncol. 2009 Mar 10;27(8):1316-22 [19164206.001]
  • [Cites] Blood. 2009 Mar 12;113(11):2375-85 [19056693.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3314-22 [19188669.001]
  • [Cites] Leukemia. 2009 Apr;23(4):746-52 [19148136.001]
  • [Cites] Blood. 2009 Apr 16;113(16):3655-65 [19221035.001]
  • [Cites] Blood. 2009 May 7;113(19):4720-8 [19278956.001]
  • [Cites] Blood. 2009 May 14;113(20):4866-74 [19264921.001]
  • [Cites] Clin Cancer Res. 2009 Jun 15;15(12):3938-46 [19509174.001]
  • [Cites] Blood. 2009 Jun 18;113(25):6411-8 [19211935.001]
  • [Cites] Leukemia. 2009 Jul;23(7):1257-63 [19148134.001]
  • [Cites] J Clin Oncol. 2009 Aug 10;27(23):3842-8 [19528372.001]
  • [Cites] Blood. 2009 Aug 13;114(7):1374-82 [19520806.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2764-73 [19546476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3710-5 [20133587.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2330-9 [11489809.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6470-83 [11533236.001]
  • [Cites] J Clin Invest. 2001 Nov;108(9):1321-30 [11696577.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12822-7 [10536006.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3315-24 [10552940.001]
  • [Cites] Br J Haematol. 2000 Mar;108(4):696-702 [10792271.001]
  • [Cites] Expert Opin Investig Drugs. 2000 Dec;9(12):2923-34 [11093362.001]
  • [Cites] Hum Mol Genet. 2001 Feb 15;10(4):395-404 [11157802.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Nat Rev Drug Discov. 2006 Jan;5(1):37-50 [16485345.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):259-69 [16557279.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5078-83 [16549775.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3330-8 [16352814.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1794-803 [16532500.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 [16641092.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5495-503 [16707479.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):6361-9 [16778214.001]
  • [Cites] J Biol Chem. 2006 Jun 30;281(26):18059-68 [16636056.001]
  • [Cites] Clin Cancer Res. 2006 Aug 1;12(15):4628-35 [16899611.001]
  • (PMID = 20029422.001).
  • [ISSN] 1474-1768
  • [Journal-full-title] Nature reviews. Cancer
  • [ISO-abbreviation] Nat. Rev. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA118319; United States / NCI NIH HHS / CA / R01 CA127277-02; United States / NCI NIH HHS / CA / CA127277-02; United States / NCI NIH HHS / CA / CA127277; United States / NCI NIH HHS / CA / R01 CA127277-03; United States / NCI NIH HHS / CA / R01 CA127277-01A1; United States / NCI NIH HHS / CA / CA118319-04; United States / NCI NIH HHS / CA / CA127277-03; United States / NCI NIH HHS / CA / R01 CA127277; United States / NCI NIH HHS / CA / CA127277-04; United States / NCI NIH HHS / CA / R01 CA118319-04; United States / NCI NIH HHS / CA / R01 CA127277-04; United States / NCI NIH HHS / CA / CA127277-01A1; United States / NCI NIH HHS / CA / CA118319
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Number-of-references] 196
  • [Other-IDs] NLM/ NIHMS246967; NLM/ PMC2972637
  •  go-up   go-down


100. Hasle H: Malignant diseases in Noonan syndrome and related disorders. Horm Res; 2009 Dec;72 Suppl 2:8-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Juvenile myelomonocytic leukemia (JMML) is a rare aggressive leukemia in young children.
  • A JMML-like myeloproliferative disorder has been described in about 30 neonates with NS and the PTPN11 mutation.
  • The disorder often regresses spontaneously, but fatal complications may occur.
  • A review of the literature indicates an increased risk of acute lymphoblastic leukemia and acute myeloid leukemia in NS.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Costello Syndrome / complications. Costello Syndrome / genetics. Female. Genetic Predisposition to Disease. Genotype. Humans. Infant. Infant, Newborn. LEOPARD Syndrome / complications. LEOPARD Syndrome / genetics. Leukemia, Myeloid, Acute / epidemiology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myelomonocytic, Juvenile / epidemiology. Leukemia, Myelomonocytic, Juvenile / genetics. Male. Neuroblastoma / epidemiology. Neuroblastoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Rhabdomyosarcoma / epidemiology. Rhabdomyosarcoma / genetics. Risk Factors. Urinary Bladder Neoplasms / epidemiology. Urinary Bladder Neoplasms / genetics

  • Genetic Alliance. consumer health - Noonan Syndrome.
  • MedlinePlus Health Information. consumer health - Cancer.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 S. Karger AG, Basel.
  • (PMID = 20029231.001).
  • [ISSN] 1423-0046
  • [Journal-full-title] Hormone research
  • [ISO-abbreviation] Horm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 49
  •  go-up   go-down






Advertisement